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Acute or reactivated viral infections are common in patients who are immunosuppressed 
because of hematopoietic stem cell transplantation (HSCT) or chemotherapy due to 
hematological malignancies. The severity of the immunosuppression, the type of immune 
functions that are affected by various therapeutic interventions, as well as underlying 
hematological malignancy contributes to viral susceptibility and clinical outcome of the 
infection. Furthermore, in patients undergoing HSCT, the serostatus of viruses with 
reactivation capacity in both the recipient and the donor must be considered, as well as the 
sociodemographic and genetic characteristics. 
Here we have studied DNA viruses that can cause clinical events in patients with malignant 
hematological diseases. Foremost, we evaluated whether it is advisable to continuously 
screen for the presence of these viruses during illness or chemotherapy in children and adults. 
In papers I and II we studied the presence of human adenovirus (HAdV) in the blood of 
patients undergoing HSCT. In papers III and IV, the presence of parvovirus B19 (B19V) in 
the bone marrow of children with various malignancies was studied, while paper V focused 
on the presence of B19V in the blood of adults and children undergoing HSCT. Paper VI 
focused on human herpesvirus 6 (HHV-6), polyoma BK virus (BKV) and B19V in the blood 
of adult patients undergoing chemotherapy for non-transplanted hematological malignancies. 
In these retrospective studies, blood and/or bone marrow samples were analyzed by 
quantitative real-time PCR for DNA representing HAdV, B19V, HHV-6 and BKV. Clinical 
and laboratory data were obtained from medical records. The proportion of patients with 
HAdV infection was relatively small, and asymptomatic infections did not occur. On the 
other hand, HAdV DNA loads >15,000 copies/mL in blood were associated with morbidity 
and mortality. Furthermore, findings of B19V in bone marrow of children undergoing 
treatment for acute lymphoblastic leukemia (ALL), were associated with prolonged 
chemotherapy. Neither B19V, HHV-6A, 6B nor BKV was common in the blood of adult 
patients with hematological malignancies who were immunosuppressed due to 
chemotherapy.  
In general, screening for these viruses in the patient groups presented may not be indicated at 
the current state. However, testing for HAdV should be performed generously when 
unexpected symptoms occur, even if they are not typical for the virus. B19V infection is 
almost always linked with some degree of cytopenia, and if unexpected cytopenia occurs in 
children undergoing chemotherapy, B19V infection should be tested for. Patients with 
primary infections normally suffer from more severe clinical disease as compared to those 
with reactivated infections. Thus, knowledge of viral serostatus in HSCT recipients and 
donors should be taken into account in diagnostic considerations. 
Overall, the diagnostic value of direct viral detection in blood and/or bone marrow samples of 
immunosuppressed patients with hematological malignancies is of considerable importance. 
Hopefully, a broad spectrum of novel antiviral compounds as well as novel procedures for 
adoptive cell therapy will be developed for these viral infections. Whether novel interventions 
will be used as pre-emptive therapy, or as symptomatic treatment, there will be an urgent 
need to monitor viral load. The present thesis can thus inform the field of clinically relevant 
viral infections and how to monitor these in selected patient categories that can be targeted 
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1.1 VIRUSES IN THE THESIS 
One cannot help but admire the strategies that various viruses have developed to invade a 
host cell and then avoid the host´s defense. Below is a brief description to understand how 
cunning viruses are, and how difficult it is to fight them. 
The viral taxonomy is constantly evolving, the name of a virus can change over time. Table 1 
describes the current taxonomy that the International Commission on Taxonomy of Viruses 
(ICTV) (1) has assigned to the viruses we report. In this thesis, the synonyms of the viruses 
used are those used in the papers (bold text). 
 
Table 1. Taxonomy of viruses 
 
 
Just for fun. The shape of the capsids of the viruses discussed here are assumed to be 
icosahedral, i.e. a closed form of 20 equilateral triangles. According to the Caspar-Klug 
theory, the 20 triangles are based on 60 subunits. The T number indicates the number of 
proteins that create one of the 60 subunits. T = 1 means one protein in each subunit, i.e. a 
total of 60 proteins form the capsid, T = 2 means two proteins each, a total of 120 proteins in 
the capsid, etc. The higher T-numbers, consist of different numbers of hexagons and always 
12 pentagons (2). HAdV: T=25; HCMV, EBV, HHV-6A, 6B: T=16; BKV: T=7; B19V: T=1. 
If the classic black and white football, designed for the 1970 World Cup, was a giant virus, it 




1.1.1 Human adenovirus (HAdV) 
1.1.1.1 Structure 
HAdVs are non-enveloped double-stranded linear DNA viruses, 26-45 kB in length, carrying 
approximately up to 40 genes. The viral capsid consists of three major proteins; 240 hexons – 
hexagon-shaped protein, 12 pentons – pentagon-shaped proteins, and 12 fiber proteins. In 
addition, there are several smaller proteins. The hexons and pentons form an icosahedral with 
20 triangular faces, 30 edges and 12 vertexes (3-5). 
The fiber proteins, one attached to each vertex, contain three structural domains 
1. The knob - the essential part in the end of the fiber that binds to a host cell receptor 
2. The shaft - that varies in length between different HAdV types and thus enables 
different interactions with host cells 
3. The binding site to the pentons vertex (4-6). 
 
1.1.1.2 Cell receptors 
The cell receptors for HAdV are: 
• CAR, the coxsackie adenovirus receptor to which most HAdVs bind  
• CD46 - preferred by HAdV species B 
• Desmoglein-2 (DSG2) – also preferred by species B 
• 2,3-linked sialic acid- a cell adhesion protein that some HAdV species D use alone 
and others in combination with CD46 (6) 
 
1.1.1.3 Replication 
HAdVs start their DNA replication with transcription of proteins, partly for further efficient 
viral DNA replication, but also to block host cell defense mechanisms, such as interferon 
production, MHC class I formation and translocation, and cell apoptosis. This is followed by 
replication to produce mature virions and capsid proteins (5-7). 
 
1.1.1.4 Species and types 
In July, 2019, HAdV had been assigned 103 genotypes (8). Here, 67 different types of HAdV 
are considered, characterized within seven species, A-G (5). The types 1-51 were identified 
by classic serum neutralization, which aimed to test the humoral immunity to the hexon, 
together with hemagglutination inhibition, in which the fiber protein was identified. Since 
serologic determinants represent less than 5-6% of the total genome, different genotypes may 
occur within the same serotype (7). The newer types 52-67 were identified by genomic 
sequencing. New types of HAdVs arise partly through recombination between two or more 
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previous genotypes (5, 7). For example, recombination of HAdV-11 and HAdV-14 resulted 
in the HAdV-55 genotype (9). New genotypes may lead to symptoms that do not occur with 
the original serotype (7). The clinical significance of genotype 68-103 is not clear in the 
literature, which is also confirmed in a compilation of HAdVs from 2019 (10). 
Co-infections with at least two HAdVs with highly similar nucleotide sequences, at 
recombination hotspots in the genome, are possible, especially in immunocompromised 
patients, where an infection can last for a long time (4, 7). 
 
1.1.1.5 Transmission 
Transmission routes are person to person – inhalation of aerosolized infected droplets, direct 
conjunctival inoculation, fecal-oral – through water, through environmental surfaces and 
instruments (fomites) (4, 5). 
At about 10 years of age, most children have been infected with some type of HAdV (11). 
Severe local outbreaks as well as nosocomial infections have been reported. HAdVs are not 
zoonotic, and only a few animal models can be used to study HAdVs (4).  
HAdVs are stable at low pH, can remain infectious in room temperature for up to 3 weeks 
and are highly resistant to physical and chemical agents. Sodium hypochlorite1 (500 ppm) for 
10 min or 70% ethanol for at least 1 minute can be used to inactivate HAdVs on surfaces  
(4, 5). 
 
1.1.1.6 Tissue tropism, infection and persistence 
Depending on HAdV type, the incubation period can be 2-14 days, and the range of clinical 
manifestations is wide (4, 5) see Table 2. Probably due to an immature adaptive immune 
system, the primary infection occurs mainly during the first five years of life (5). 
The diversity of clinical manifestations shows that HAdV tropism varies by viral type. After 
primary infection, latent viruses, i.e. viruses that express viral proteins but not virions, persist 






Table 2. HAdV and clinical manifestations (4, 5, 7, 12, 13). 




1.1.2 Epstein-Barr virus (EBV), Human cytomegalovirus (HCMV), Human 
herpesvirus 6A and 6B (HHV-6A) and (HHV-6B) 
This thesis includes studies on HHV-6A and HHV-6B in paper VI. Herpes viruses in general 
are fascinating and often occur in patients discussed in the other papers, e.g. paper I. To 
understand the challenges of these viruses, several of them are briefly presented here. 
 
1.1.2.1 Structure 
The four viruses are large enveloped double-stranded linear DNA viruses with an icosahedral 
capsid protected by a proteinaceous layer, the tegument. The envelope is a lipid bilayer that 
contains various proteins, e.g. three proteins conserved throughout the herpesviridae, and also 
species-unique proteins. The proteins are involved in binding to target cells - viral tropism - 
and ensure that the virus enters the cell (14-20). 
 
1.1.2.2 Entry into the cell 
The four viruses have slightly different strategies for binding to cells. Common between the 
viruses is the fusion machinery. Two conserved proteins, which form a dimer, regulate a third 
conserved protein, which activates the fusion machinery, ensuring entry of the virus either via 
direct fusion with the cell membrane or via the endosome membrane through endocytosis. 
The dimer often - but not always - forms complexes with species-specific proteins (15) and 
this determines viral tropism (21, 22) 
Several different cell proteins, receptors and co-receptors that facilitate the entries of the 
viruses, have been identified. New cellular proteins used by the viruses are still being 
discovered (14, 17, 20, 21, 23-26). 
EBV: The entry into B cells is by endocytosis (14, 15). The exact mechanism for the virus to 
enter epithelial cells is less well known. Direct fusion between virus and cell membrane is an 
accepted route, but it is possible that entry can also occur via endocytosis (21, 23).  
HCMV: The conserved regulatory dimer, see above, forms either trimer or pentamer 
complexes with species-specific proteins. Upon formation of a trimer, the virus can enter 
fibroblasts by direct fusion. In the formation of pentamers, the virus enters many cell types 
through endocytosis (17, 21, 24). 
HHV-6A, 6B: HHV-6 consists of two separate viruses, type 6A and type 6B with a 90% 
identic genome (27) entering the cells via different receptors. HHV-6A enters via CD46 - also 
preferred by HAdV species B - and HHV-6B enters via CD134, which is part of the TNF-





EBV: It is discussed whether the virus at the time of transmission passively passes 
(transcytosis) or infects the oropharyngeal epithelial cells before infection of B cells in the 
underlying lymph tissue, i.e. tonsils and adenoids (Waldeyer's ring). It is clear, however, that 
epithelial cells in the throat can be infected with actively replicating virus present in the B 
cells located in Waldeyer's ring (30, 31).  
HCMV: The virus thrives in all tissues with epithelial cells, endothelial cells, hematopoietic 
cells (monocytic lineage), fibroblasts, smooth muscle cells, hepatocytes, neuronal cells or 
trophoblasts. Infection of epithelial cells occurs mainly due to transmission between hosts, 
while other cells become infected due to systemic spread within the infected host. HCMV can 
proliferate efficiently in fibroblasts and smooth muscle cells. Different tropism for e.g. 
endothelial cells, macrophages and dendritic cells are due to differences in the HCMV strain. 
(32). 
HHV-6A, 6B: Both species infect essentially the same cells; CD4+ T cells, CD8+ T cells, 
monocytes, macrophages, hematopoietic cells in the bone marrow, epithelial cells in the 
kidneys and salivary glands, endothelial cells, astrocytes, oligodendrocytes, microglial cells,  
and gametes (19). Unique properties of HHV-6A, 6B include that a DNA sequence in the 
viral genome corresponds to the DNA sequence of human telomeres. By homologous 
recombination (i.e. two identical DNA sequences are exchanged between genomes) in an 
infected cell, the virus can be incorporated into the telomeres (33).  
 
1.1.2.4 Transmission 
These four species of herpesviruses are human specific, and transmission occurs mostly from 
person to person through body secretions (34). They have the ability to use 
monocytes/macrophages to spread the infection within the host (35). 
EBV: The transmission is through saliva. Worldwide, more than 90% of the adults are 
infected (34). In the primary infection, large amounts of viruses derived from oropharyngeal 
epithelial cells (36) can be shed between one month and three years (31). In the latent stage, 
virus shedding is constant and fluctuates over time in the individual (30). Transmission via 
blood products is a possible, but not common route. Transmission is also possible in patients 
undergoing hematopoietic stem cell transplantation. The transmission route for young 
children is not known, but transmission from infected caregivers, siblings, etc. is possible. 
There is no evidence of transmission via fomites (31). 
HCMV: The transmission is through exposure to infected body secretions such as saliva, 
urine, feces, semen, blood (e.g. transfusions and transplants) etc, which may come in contact 
with mucosal epithelial cells – or endothelial cells – of an uninfected person (37). 
Seroprevalence increases with age (38) and more than 80% are infected worldwide (39). In 
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connection with the primary infection, infants and young children can continuously shed 
HCMV for several years, roughly speaking, while adults can shed for up to half a year. 
After primary infection, intermittent shedding can occur in both children and adults (37). 
HCMV can be transmitted through the placenta from mother to fetus and by breastfeeding – 
30-40% of HCMV-positive women who breastfeed transmit the virus to their children (32). 
Reinfection with a new strain of HCMV may occur (40). Viable HCMV can survive on 
different surfaces between 1-6 hours (41). 
HHV-6A, 6B: The transmission is via intermittent viral shedding from saliva. At least 90% of 
adults worldwide are infected (42). The virus can be transmitted from woman to fetus via the 
placenta. Through virus-infected gametes – eggs or sperm – the virus can be transmitted to 
the fetus during pregnancy (Mendelian inheritance), where a complete viral genome is 
integrated into chromosomes in all cells, i.e. inherited chromosomally integrated HHV-6A, 
6B (iciHHV-6A, 6B) (43, 44). In these cases, viral load of HHV-6A, 6B DNA in whole blood 
exceed 5.5 log10 copies/mL. To confirm iciHHV-6A, 6B, tissues normally not infected with 
the viral DNA, e.g. hair roots, can be analyzed (44). About 1% are infected at birth (19).  
 
1.1.2.5 Infection, persistence and reactivation in immunocompetent individuals 
Herpesviruses remain in the host for the rest of the host's life, mostly in latency. EBV and 
HCMV persist as extrachromosomal episomes, (i.e. circular DNA) in the cell nucleus (45-47) 
while HHV-6A, 6B are integrated to the telomeres, see above. 
EBV: Primary infection. In children most infections are asymptomatic or have nonspecific 
symptoms (34). In adolescent and adults, infectious mononucleosis, with the classical 
symptoms of fever, pharyngitis, cervical lymphadenopathy and fatigue are common 
symptoms (31). Approximately 90% of patients with infectious mononucleosis have EBV as 
a cause. CMV, HHV-6B and HAdV (and some other pathogens which are not discussed 
further here) can also mimic the symptoms (48). 
Persistent latency. When B cells become infected, they are activated to proliferating blasts 
and migrate to the lymph nodes, where they are transformed into dormant memory-B cells. 
These cells spread to the peripheral circulation, where they divide and at the same time also 
replicate viral DNA, which is transferred to the daughter cells. Resting memory-B cells do 
not express viral proteins on the cell surface and divide as normal memory-B cells, which 
means that the host´s immune system cannot distinguish infected memory-B cells from 
uninfected. It is unclear which signal causes these memory-B cell to differentiate into plasma 
cells, but it is the differentiation itself that initiates the viral replication (30, 31). Epithelial 
cells are also replication sites during latency, but whether the cells can also harbor the virus 
through persistence is unclear (30). 
Malignancies. The EBV genome encodes for latent proteins that can cause cell proliferation 
in B cells and there is convincing evidence associating EBV with Hodgkin lymphoma, 
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Burkitt lymphoma and lymphoma in immunosuppressed individuals such as post-transplant 
lymphoproliferative disease (PTLD) (30).  
HCMV: Primary infection. The primary infection can occur already in utero and up to 
adulthood. Fetuses can die or suffer from serious complications. In children, adolescents and 
adults, the infection is often asymptomatic although non-specific symptoms (40) or 
symptoms such as infectious mononucleosis may occur (48). 
Persistent latency and reactivation. In immunocompetent individuals, the virus reactivates 
intermittently and triggers the adaptive immune system to regain control of viral replication 
(49). HCMV has the ability to spread to all organs, via blood, but the immune system 
prevents serious diseases. Even at a so-called quiet stage, at least 1% of the peripheral T cells 
control HCMV, which means that the immune system uses more resources for this virus than 
for any other virus (40). There are many indications that events in the normal cell cycle may 
be sufficient to trigger virus activation (50). 
HHV-6A, 6B: Primary infection. Most often the infection occurs in early childhood, where 
HHV-6B presents high fever followed by rash (exanthema subitum = roseola infantum = 
sixth disease) as the most common symptoms (51). Less is known about primary HHV-6A 
infection, but it may be associated with fever, without the rash (44, 52). The amount of HHV-
6A, 6B DNA in various body fluids is elevated in an acute infection, but the viral load is 
never as high as in individuals with iciHHV-6A, 6B, see above (44). 
Persistent latency. HHV-6B, 6A prefer to persist in latency in monocytes and macrophages in 
peripheral blood, but can persist in hematopoietic progenitor cells as well as other cells 
including T cells and probably neuronal cells (19, 53, 54). It is not entirely clear whether 
iciHHV-6A, 6B can produce active virions (54). 
Reactivation. Some drugs may reactivate or increase the replication of viral DNA, which may 
cause eosinophilia and rash symptoms. Examples of drugs are vancomycin (antibiotics), 
carbamazepine and phenytoin (antiepileptics), ibuprofen and naproxen (NSAID and, 
allopurinol (anti hyperuricemia) (44). 
 
1.1.3 Human parvovirus B19 (B19V) 
1.1.3.1 Structure 
There are three distinct genotypes of B19V; 1, 2 and 3. Genotype 2 is not in circulation, and 
genotype 3 is endemic in some areas as Ghana, Brazil and India (55). Here we discuss 
genotype 1. 
B19V is a non-enveloped single stranded linear DNA virus, 5.6 kB in length, carrying 5 
genes. The icosahedral capsid consists of 60 protein structures (VPs), divided into VP1 and 
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VP2 in a ratio of about 1:20. A large part of the genome consists of the non-structural NS1 
protein. The genome also encodes two small non-structural proteins (55).  
Capsid proteins. The VPs are immunogenic and CD4+ T cells can be triggered by VP 
epitopes. IgM and IgG antibodies are directed against VPs. VP1 is involved in the binding of 
the virus to the cell and enables subsequent endocytosis. VP2 is involved in the production 
and installation of new capsids, consisting of VP1 and VP2, inside the cell (55). 
The non-structural NS1 protein. The most essential and multi-functional protein in B19V is 
the NS1 protein, which is involved in viral DNA replication and folding, and also in the 
packaging of DNA into capsids, by regulating e.g. the cell cycle and various cell genes. NS1 
is also thought to affect the cell's defense system (56). 
 
1.1.3.2 Cell receptors 
Using the cell protein Ku80, B19V attaches to the cell glycoprotein globoside (synonymous 
with erythrocyte P antigen), which activates the viral protein VP1 to prepare for endocytosis. 
During internalization, B19V need to interact with the cellular protein α5β1 integrin. If this 
interaction does not work, the virus detaches and repeats the procedure (57). 
 
1.1.3.3 Tropism 
The virus infects different stages of erythroid progenitor cells in bone marrow and in fetal 
liver (58, 59). 
 
1.1.3.4 Transmission 
The transmission is via the respiratory route probably through droplets, but no specific 
respiratory symptoms are present. The virus can also transmit via blood products or through 
transplantation. Also, transmission from infected surfaces is possible. In pregnancy B19V can 
be transmitted from woman to fetus via the placenta. Seroprevalence rates vary around the 




Primary infection. The typical clinical manifestation in children, 5 to 15 years, are symptoms 
such as fever and red girth-shaped rashes also called erythema infectiosum or the fifth 
disease. In both children and adults, stomach ache, nausea, diarrhea and arthralgia may occur. 
Infection before the 20th week of pregnancy can lead to hydrops fetalis and fetal death (55). 
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In more severe cases, B19V can cause hemolytic anemia as well as thrombocytopenia, 
neutropenia, granulocytopenia and even pancytopenia (60). 
Persistent infection. B19V DNA can persist lifelong in skin, synovium, tonsil liver, bone 
marrow, colon, heart, lymphoid-, testicular-, and thyroid tissues (60, 61). B19V DNA, 
together with other genotypes of parvovirus, have been discovered in skeletons from Finnish 
World War II victims (62). However, the immune response against B19V is strong. B19V 
specific T cells together with neutralizing antibodies, directed against some epitopes on VP1 
and VP2, confer lifelong protection against reinfections (55).  
 
1.1.4 BK polyomavirus (BKV) 
1.1.4.1 Structure 
BKV is a non-enveloped double-stranded circular DNA virus. The capsid is icosahedral, 
consisting of three viral proteins (VPs), where VP1 is the most common protein. Inside the 
capsid there are three additional proteins (63). BKV has at least five genotypes which are 
completely distinct serotypes – Ib1, Ib2, II, III, IV (64).  
 
1.1.4.2 Tropism 
The different genotypes may have different tropism (64). At least BKV I enters the urinary 
epithelium via endocytosis (63). BKV has been found in other cells as well, e.g. peripheral 
leukocytes, fibroblasts, lymphoid tissues as tonsils etc. (63, 65, 66). 
 
1.1.4.3 Transmission 
Transmission occurs from human to human in early childhood, according to seroconversion, 
but the exact route is not known (63). Transmission via respiration droplets has been 
suggested (66), but it is uncertain whether the virus causes respiratory infections (67), 
although it is detected in saliva (68). Also, transmission via the fecal-oral route has been 
suggested (63). Some immunocompetent individuals shed low levels of virions in the urine 
(69, 70). In addition, other routes e.g. as via placenta or via infected water have been 
discussed (63).  
Seroprevalence rates vary between different populations, but in Europe approximately  






Primary infection. Symptoms are absent or mild in the immunocompetent person (63).  
Persistent infection. During latency, BKV is found in the urinary tract and kidneys. 
Immunocompetent individuals do not reactivate the virus, but in immunosuppressed patients, 
viral reactivation can cause symptoms and disorders from the urinary tract and kidneys, e.g. 
hemorrhagic cystitis and polyomavirus-associated nephropathy (63).  
 
 
1.2 INNATE AND ADAPTIVE IMMUNE RESPONSES IN VIRAL INFECTIONS 
When the external barriers do not prevent virus entry, the first line of the body's defense 
system is innate cells, e.g. dendritic cells (DCs), macrophages, monocytes, granulocytes and 
NK cells, as well as epithelial cells and endothelial cells. The complement system and other 
acute phase proteins also belong to the defense system, but this is not discussed further here. 
To eliminate, or at least minimize, an infection, the next line of defense, consisting of T cells 
and B cells, is also needed, but is discussed here very briefly. An overview of the 
hematopoietic and immune system is presented in Figure 1. 
 
 
Figure 1. An overview of the hematopoietic and immune system. 
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All nuclear-containing body cells express on their surfaces, major histocompatibility class I 
(MHC-I) molecules that present peptides produced in the cell. Antigen presenting cells 
(APCs) i.e. DCs, macrophages, B cells and Langerhans cells have the ability to present 
peptides from endocytosed or phagocytosed antigens via MHC-II (71). 
Viruses have specific conserved structures – pathogen associated molecular patterns 
(PAMPs), which differ from host molecules. In viruses, envelope proteins, double stranded 
(ds) RNA, single stranded (ss) RNA and DNA sequences – especially containing 
unmethylated cytidine-phosphate-guanosine (CpG) motifs – form PAMPs (72). Many cells in 
the defense system have pattern recognition receptors (PRRs) that can recognize PAMPs. 
When detected, the viruses are endo- or phagocytosed (73-75).  
 
1.2.1 Virus-recognizing PRRs in humans 
1.2.1.1 Toll-like receptors (TLRs) 
Six of 10 different transmembrane TLRs in humans can detect viruses and are expressed in 
monocytes, macrophages, DCs, neutrophils, B cells, T cells, fibroblasts, endothelial cells and 
epithelial cells. TLR2 and TLR4, expressed at cell membranes, are activated by viral 
envelope glycoproteins. Intracellular TLRs expressed in the endosomal membranes are TLR3 
- activated by dsRNA, TLR 7 and 8 - activated by ssRNA and TLR9 - activated by DNA with 
unmethylated CpG. Activation of TLRs initiate the production of various cytokines, often 
type I interferon (IFN) (72, 74-76). 
 
1.2.1.2 C-type lectin receptors (CLRs) 
CLRs are mostly transmembrane receptors on cell membranes that interact with other 
intracellular PRRs and support antiviral actions. They are expressed on DCs, macrophages, 
monocytes and Langerhans cells. Soluble CLRs in the bloodstream act together with the 
complement system. Unfortunately, some viruses have the ability to exploit transmembrane 
CLRs, often DC-SIGN, to enter cells, avoid antiviral machinery and transmit to other cells to 
spread the infection (77, 78). 
 
1.2.1.3 Retinoic acid-inducible gene I (RIG-I) like receptors (RLRs) 
RLRs are cytoplasmic receptors, in myeloid and epithelial cells, as well as in cells of the 
central nervous system. They bind dsRNA or ssRNA from replicating RNA viruses and also 
bind small RNA fragments encoded from EBV. When activated, RLRs initiate signaling 




1.2.1.4 Nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) 
NLRs are intracellular receptors where at least two out of 22 members can detect viral RNA. 
NLRs contribute to IFN production (80, 81). 
 
1.2.1.5 DNA-sensors 
DNA sensors, e.g. stimulator of interferon genes (STING), are intracellular molecules in 
DCs, macrophages and fibroblasts that have the ability to detect cytoplasmic dsDNA and 
stimulate type I IFN production (82).  
 
1.2.2 Interferon (IFN) 
1.2.2.1 Type I IFN 
When viruses bind to type I IFN-initiating PRRs, interferon-regulating factors (IRFs) are 
upregulated, inducing transcription of type I IFNs, which have paracrine and autocrine 
functions. Type I IFNs stimulate proliferation, expansion and differentiation of the cells of 
the immune system. Many non-immunological cells have type I IFN receptors on the cell 
surface, which increases the transcription of IFN-dependent genes. These affect the synthesis 
of cell proteins, inhibit cell growth and induce apoptosis which result in an inhospitable 
environment for viruses (77, 83).  
 
1.2.2.2 Type II IFN 
IFN-γ is a type II IFN which is produced by NK cells, NKT cells (not discussed further), 
activated CD8+ T cells and CD4+ T cells polarized as T helper 1 (Th1) cells. For example, 
IFN-γ initiates Th1 cell differentiation, stimulates macrophages and B cells and increases the 
transcription of MHC molecules in different cells (84). 
 
1.2.3 Dendritic cells (DCs) 
Virus uptake, or viral protein and peptide uptake, affects several functions of DCs, such as 
upregulation of MHC-II to present viral peptides (71), and also make MHC-I available to 
these peptides, whether DCs are infected or not (cross-presentation) (85). 
With MHC-bound peptides and various DC-produced cytokines, both CD8+ T cells and 
CD4+ T cells are activated. Type I IFN together with certain cytokines stimulates NK cells, 
and type I IFN together with other cytokines activates B cells into plasma cells and enhances 
antibody production (86). The Conventional DCs (cDCs) or myeloid DCs (mDCs) are found 
mainly in barrier and lymphoid tissues. Immature cDCs located in the mucosa strongly 
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express CLRs (e.g. DC SIGN) in their cell membrane. In the cytoplasm, TLR3 and TLR9 are 
expressed which detect viral RNA. When activated, the cDCs migrate to nearby lymph nodes 
and present the antigen to naive T cells. cDCs produce cytokines, e.g. type I IFN and type II 
IFN (87, 88). Plasmacytoid DCs (pDCs) express cytoplasmic TLR7 and TLR 9 as PRRs. 
They circulate mostly in the bloodstream and when activated they produce large amounts of 
type I IFN (89).  
Other DCs, e.g. monocyte derived DCs, Langerhans cells etc. are not further discussed here.  
 
1.2.4 Monocytes and macrophages 
Monocytes are non-dividing receptor-rich cells with high phagocytic and antigen presenting 
capacity via MHC-II. When monocytes encounter viruses they activate and transform into 
macrophages (35). Antigen uptake by monocytes and macrophages occur approximately the 
same way as in DCs (78). There are several phenotypes of macrophages. The “classical” 
main groups are M1 macrophages that respond to infectious agents and M2 macrophages 
involved in tissue repair, the latter not further discussed here even though there is no clear 
boundary between M1 and M2. M1 macrophages are activated by antigens, cytokines, e.g. 
type II IFN and TNF- (90) and by direct co-stimulatory contact (CD40) of Th1 cells which 
increase a non-specific phagocytosis of antigens and matrix debris (90, 91). Macrophages 
stimulate CD4+ T cells into Th1 cells by direct co-stimulatory contact (e.g. CD80) and 
produce various cytokines that contribute to inflammation (90).  
 
1.2.5 Natural killer (NK) cells 
About 5-10% of lymphocytes are NK cells, which without prior antigen presentation destroy 
defective cells using cytotoxic granules (71). Type I IFN and DC- or macrophage-derived 
cytokines stimulate NK cells to develop and mature (89, 92). To avoid destroying healthy 
cells, NK cells have killer inhibition receptors (KIR) that recognize cells with sufficient 
expression of MHC I on the cell surfaces. NK cells destroy other cells when they 
downregulate their MHC-Is, when they produce stress molecules due to infection and when 
the NK cells´ antibody receptors (Fc--receptors) detect antibodies bound to the cells - a 
process called antibody-dependent cell-mediated cytotoxicity (ADCC) (71, 93). NK cells 
produce various cytokines e.g. type II IFN to enhance response from other immune cells (94). 
NK cells are usually considered to be part of the innate immune system. However, some NK 
cells are considered to have memory-like functions. The "memory" consists of these NK cells 
being activated by e.g. certain combinations of cytokines to which it has previously been 
exposed, or via the actual activating of the NK cell receptor itself – it is not bound to any 
specific antigen. As a result of this adaptation, it can be said that memory-like NK cells are 
part of the adaptive immune system (95). 
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1.2.6 T cells 
1.2.6.1 Naive T cells 
Naive T cells circulate in the bloodstream and lymphoid tissues and when they encounter 
APCs in the lymph nodes, they can be activated if they: 1) detect antigen presented on the 
APCs MHC-I or MHC-II, 2) are stimulated by special co-stimulating molecules on the APCs, 
e.g. CD80 or CD86 and 3) can interpret the cytokines that APCs express and differentiate 
based on them (96, 97).  
 
1.2.6.2 CD4+ T cells 
After antigen priming via MHC-II mainly DCs and NK cells stimulate CD4+ T cells with IL-
12 or type II IFN, respectively, to differentiate into Th1 cells. Th1 cells in turn activate DCs, 
macrophages and B cells through direct contact with their CD40 receptors (91) and produce 
various proteins as IL-2, type II IFN and lymphotoxin  (LT) – the latter not further 
discussed here. IL-2 is important for activation of CD8+ T cells (98), activation of B cells 
(99) and CD4 T cell memory (100, 101). Type II IFN activates e.g. macrophages (102). Other 
CD4+ T cell subsets are not further discussed here. 
 
1.2.6.3 CD8+ T cells 
After antigen priming via MHC-I and activation with type I IFN from DCs, IL-2 from Th1 
cells together with IL-12 from APCs, stimulate naive CD8+ T cells to differentiate and 
replicate to large numbers of cytotoxic T cells (CTLs), enter the bloodstream, and transport to 
the site of infection. In a feed-forward loop, CD8+ T cells help to stimulate DCs, where 
CD4+ T cells also are involved, see above. When the infection is cleared, most CTLs die, and 
only a small amount remains, which will be included in the group of memory cells. CTLs 
produce type II IFN, TFN- and the cytotoxic proteins perforin and granzyme B. To prevent 
tissue damage during viral infection, a subset of CTLs also produce IL-10 (98).  
 
1.2.6.4 Memory T cells 
In various studies, attempts have been made to define memory T cells without a uniform 
definition being achieved. Briefly, they are long-living and can reside in lymphoid and non-
lymphoid tissues. Residing CTLs have a lower activation threshold than naive CD8+ T cells 
and can be activated without help from Th1 cells. T cell memory appears to be a 




1.2.7 B cells 
Despite extensive maturation steps in the bone marrow, the “conventional” B cells, with their 
functional immunoglobulin (Ig) M (IgM) B cell receptors (BCRs), and ability to capture 
viruses and present antigen peptides on MHC-II or MHC-I, are not fully mature when they 
enter the bloodstream. The antigen-presenting B cells mature fully in a 7-day machinery for 
proliferation and differentiation into isotype-specific IgG-producing plasma cells and IgG-
isotype-switched memory B cells, after direct co-stimulatory contact (CD40) with cytokine 
secretory (IL-2) Th1 cells in secondary lymphoid tissues such as the spleen and lymph nodes. 
Memory B cells migrate between circulation and secondary lymphoid organs. When an 
antigen is detected, they must be stimulated by Th1 cells to differentiate into plasma cells and 
produce isotype-specific antibodies, but do not go into an extensive cell proliferation (104, 
105).  
Antibodies (i.e. immunoglobulins) are either BCRs on the B cell surface or secreted outside 
the cell and aim to bind to antigens, activate macrophages and other immune cells and 
activate the complement system (104). Neutralizing antibodies, usually IgG or IgA, are 
produced in a primary e.g. viral infection, and when a reinfection occur, they bind to the viral 
antigen and prevent the virus from attaching to cell receptors (71). 
A minor subset of B cells derived from the bone marrow, located in the marginal zone of the 
spleen, functions as innate cells and recognize carbohydrate or glycolipid antigens by either 
BCRs or TLRs. They can produce IgMs against antigen within 1-3 days, without being 
activated by Th1 cells. Another subgroup, called B1 cells and derived from the fetal liver, 
works in a similar way (104, 105).  
 
1.2.8 Summary 
1.2.8.1 Activated APCs 
DCs present antigens to naive T cells, which are activated and become Th1 cells. 
Macrophages present antigen to Th1 cells, which activate CD8+ T cells to CTLs, which in 
turn kill the activated macrophages and infected cells. Both DC and macrophages can be used 
to transmit viruses to other cells. B cells present antigens to Th1 cells, which stimulates the B 
cells to produce antibodies. 
 
1.2.8.2 Immunity 
Virus-specific proteins determine which cell receptor to bind and infect a specific cell type 
via endocytosis, phagocytosis or membrane fusion. Memory B cells and memory T cells can 
recognize a previously known virus. The former immediately begin to produce antibodies, the 
latter take some time and begin to act when viral antigens are presented by MHC molecules, 
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meaning that viruses have already had time to infect cells. Immunity means that neutralizing 
antibodies secreted from activated memory B cells prevent virus-specific proteins from 
attaching to cell receptors. 
 
 
1.3 HEMATOLOGICAL MALIGNANCIES 
The classifications of hematological diseases have changed a lot over the years. Sometimes a 
disease has been a lymphoma and then a leukemia and then again, a… - very confusing. 
Below is an attempt to present the various hematological malignancies that currently apply. 
At the end of this section, Figure 2 presents an overview of hematological malignancies. 
 
1.3.1 Acute lymphoblastic leukemia (ALL) 
ALL is characterized by a malignant proliferation of lymphoblasts in the blood and bone 
marrow. ALL is often formed de novo, but a chronic myeloid leukemia (see below) can turn 
into an ALL. Note, despite the name of the chronic disease, ALL never involves cells from 
the myeloid lineage. ALL is classified into three main types. The most common is precursor-
B ALL (formerly B-lymphoblastic lymphoma). Others are T cell ALL (formerly T-
lymphoblastic lymphoma), and the relatively rare Burkitt leukemia (same as Burkitt 
lymphoma, formerly B cell ALL) (106, 107). 
 
1.3.2 Acute myeloid leukemia (AML) 
Characteristic of AML is that at least 20% of the nucleated cells in the blood or bone marrow 
are proliferating malignant myeloid precursors. The disease never involves cells from the 
lymphoid lineage. Chronic myeloid leukemia (see below) and myelodysplastic syndrome can 
turn into AML. There are many different types of AML, and there are two different 
classification systems. The old classification – French-American-British classification (FAB) 
was based on the appearance of the cells (cell morphology) that labeled the different types of 
AML with numbers, AML-M0, AML-M1… … AML-M7. The newer classification – the 
WHO classification – divides the types of AML into 5 classes based on morphology, genetic 
changes, previous therapies e.g. chemotherapy (such as busulfan or cyclophosphamide 





1.3.3 Myelodysplastic syndrome (MDS)  
In MDS, heterogeneous dysplastic changes occur in myeloid cells and there may, but need 
not, be an increase in blasts. Recent studies point to a disorder in a hematopoietic stem cell. 
The cytopathologic picture is abnormal erythrocytes, neutrophils and/or megakaryocytes. 
There are 6 types of MDSs, based on different dysplastic changes, e.g. refractory anemia with 
excess of blasts (RAEB), an aggressive type with high risk of converting to AML  
(107, 109, 110). 
 
1.3.4 Chronic lymphoproliferative disorder (CLD). 
The malignancy originates from relatively mature lymphoid cells, not from stem cells. 
The most common type is chronic lymphocytic leukemia (CLL), also known as small 
lymphocytic lymphoma, which is characterized by mature-appearing B cells that infiltrate 
lymphatic organs, including blood and bone marrow. Some patients with CLL have 
hypogammaglobulinemia, which may increase susceptibility to infection. CLD also includes 
hairy cell leukemia, a rare form that originates in B cells, with primary sites in the blood, 
bone marrow and spleen. Monocytopenia is always present and pancytopenia is common. 
Other rare CLDs are prolymphocytic leukemia, an aggressive disease, mostly B cell type, and 
large granulated lymphocyte leukemia, the cell type being T- or NK cells (107, 108). 
 
1.3.5 Chronic myeloproliferative disorder (CMD).  
The disease originates in immature early stem cells before differentiation into myeloid or 
lymphoid stem cells. Tyrosine kinase-dependent growth receptors are constantly activated, 
forcing cells in different stages of maturation to proliferate. CMDs can turn into acute 
leukemias. CMD includes chronic myeloid leukemia (CML), characterized by high 
proliferation of neutrophils and their precursors in the bone marrow and blood, polycythemia 
vera, which affects the erythrocytic lineage, essential thrombocythemia and chronic 
myelofibrosis, which is characterized by marrow fibrosis (106-108). 
 
1.3.6 Myeloma 
Myeloma is a lymphoproliferative disorder in which malignant monoclonal plasma cells 
(from the B cell line), located in the bone marrow, produce large amounts of monoclonal 





The disease begins in a lymph node or in a lymphoid tissue with cells that are sometimes 
morphologically and immunophenotypically identical to those seen in leukemias. The 
lymphomas are divided into two main groups, Hodgkin- and non-Hodgkin lymphoma (NHL). 
Hodgkin lymphoma, with few subtypes, originates from lymph nodes and spreads to adjacent 
nodes. NHL, with many different subtypes, originates and spreads between lymph nodes 
and/or lymphoid tissues in a rather unpredictable manner.  
Different classification systems for lymphomas have been used over the years and the 




Figure 2. An overview of hematological malignancies.  
Abbreviations: ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; CLL: Chronic 







1.4 HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) 
1.4.1 Allogenic grafts 
Every individual has four haplotypes of human leukocyte antigen (HLA), two each from 
father and mother, respectively. Optimal is if the donor and the recipient have identical HLA. 
A matched unrelated donor (MUD) is a donor not related to the recipient, but where HLA 
matches well enough. 
 
1.4.1.1 Source of grafts 
Peripheral blood stem cells (PBSCs). The donor's bone marrow is stimulated to increase the 
production of stem cells into the bloodstream, where they can be harvested from a peripheral 
blood vessel for 3-5 hours (111). 
Bone marrow is taken from the donor´s hip bone. The method is currently used for patients 
who have non-malignant diseases, or if the donor is too young to be able to lie still for as long 
as a peripheral harvest takes (111). Cells from bone marrow give less risk of GvHD and of 
transplant-related death (112). 
Umbilical cord cells from the placenta are recovered at the birth of a sibling or retrieved from 
an umbilical cord bank. The cells are immature and can be used when it is difficult to match 
the HLA between the recipient and the donor. In special cases, cells from two umbilical cord 
donors can be combined (111). 
 
1.4.2 Conditioning 
Conditioning before HSCT is performed for two purposes: Reduce the amount of tumor cells 
and depress the recipient's immune system so that the donor's cells can engraft. A 
myeloablative conditioning (MC) consists of alkylated agents2, often supplemented with total 
body irradiation (TBI). The patient's hematopoiesis is completely eliminated and cannot 
recover. A less toxic but still immunosuppressive regimen is the reduced intensity 
conditioning (RIC). Very simplified, RIC differs from MC in that the alkylating agents or 
TBI are reduced by about 30%. To prevent graft rejection and to prevent GvHD, patients 
often receive antibodies directed against T cells during conditioning. The exact conditioning 
regimen varies between patients and is based on the underlying diagnosis, age, comorbid 
factors etc. (113). 
 
 
2 Alkylating agents attach alkyl groups (CnH2n+1) covalently to nucleic acid bases of DNA (usually guanine), 
leading to cross-linking of DNA, causing strain breakdown and inhibition of replication. 
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1.4.3 T cell depletion 
Anti-thymocyte globulin (ATG) is purified IgG fractions of sera from pathogen-free rabbits, 
horses or sometimes goats, who have been immunized with human thymocytes or T cell 
lines. The effects of ATG are depletion of circulating T cells and interference with B cells, 
NK cells and dendritic cells (114, 115). 
Alemtuzumab is an antibody directed against the protein CD52, expressed on both T- and B 
cells, but not on hematopoietic stem cells. When alemtuzumab is bound to the lymphocyte, 
either NK cells will destroy the lymphocytes through antibody-dependent cellular 
cytotoxicity, or the complement system is activated, which destroys the cells through osmotic 
lysis (116). 
 
1.5 THE IMMUNOSUPPRESSED PATIENT 
The impressive and complex immune system sometimes fails with its replication, signaling 
and self-regulation, which is not surprising given all the components and sub-steps involved. 
Unfortunately, failures can lead to the development of serious hematological diseases, as 
described above. 
Therapies for hematological malignancies and stem cell transplantation aim to suppress or 
eliminate defective cells to replace them with functional cells. An undesirable effect of the 
treatment is that all parts of the hematopoietic system are affected, i.e. even the cells that 
functioned properly, which in turn means that the immune system becomes dysfunctional and 
patients become immunosuppressed. 
Immunosuppression may increase the susceptibility to infections and contribute to increased 
morbidity and mortality, compared to individuals with a functioning immune system. 
In viral infections, many symptoms depend on the immune system's response to the virus. 
However, diagnosing a viral infection only by interpreting the symptoms is a challenge, 
especially in immunosuppressed patients. The immunosuppressed patient does not always 
express the symptoms expected from a particular virus. In addition, the symptoms may debut 
later than expected and they may also be misinterpreted as symptoms of a treatment or the 
underlying disease, e.g. malignancy. This means that it is not possible to rely solely on 
symptomatology to diagnose a viral infection. 
In the section on viruses above, a brief review has been made regarding viral tropism. This 
means that organs that contain these cells can be affected by a viral infection, and that the 
infection becomes more ruthless if the patient is immunosuppressed. In the literature, there 
are a variety of descriptions of various serious viral infections that can occur in 
immunosuppressed patients. In this introduction, we do not go on to describe the infections 
themselves, but we are content to state that viral infections in immunosuppressed patients are 
of evil, and should be detected early. 
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1.6 PRINCIPLES FOR ANALYSIS METHODS IN THIS THESIS 
Sample material that has been analyzed is: 
• Whole blood: All blood components remain, i.e. cells – erythrocytes, leukocytes and 
thrombocytes - as well as proteins and coagulation factors. 
• Blood plasma: All cells have been removed, but proteins - including 
immunoglobulins - and coagulation factors as well as fibrinogen remain 
• Serum: All cells and coagulation proteins have been removed, but other proteins such 
as immunoglobulins remain. 
• Bone marrow: A soft tissue found in the hollow parts of the hip bone and sternum, 
containing hematopoietic stem cells. 
 
1.6.1 Polymerase chain reaction (PCR) 
PCR is a method that allows a predetermined DNA sequence to be copied, i.e. amplified, in 
large quantities (117, 118). The method can also be used for RNA, but this will not be 
discussed further here. 
To perform a DNA PCR, the following components are needed 
• a copier for the DNA sequence – a DNA polymerase  
• a start point for the copying – a primer 
• building blocks for creating copies of DNA – deoxyribonucleotide triphosphates 
(dNTPs)  
• suitable equipment and environment for the above 
1.6.1.1 DNA polymerase 
DNA polymerases have the ability to read DNA and build a complementary new DNA 
sequence while reading. The bonds between the nucleotides in DNA are strictly regulated. In 
one direction there is always a free hydroxyl group (3 'end) and in the other a free phosphate 
group (5' end). The DNA polymerases always start at the 3´end, and read towards the 5´end. 
Since the creation of the new DNA sequence is complementary, the new DNA strand is 
formed in a 5´-3´direction. The DNA polymerases used in PCR are often so-called Taq-
polymerases, heat-resistant enzymes derived from the bacteria, Thermus aquaticus (119).  
1.6.1.2 Primers 
To know where to start amplifying, the DNA polymerases needs starting points, primers. The 
primers consist of about 20 nucleotides and are complementary bound to the DNA sequences 
to be copied. Because PCR technology produces double-stranded DNA (dsDNA), hybridized 
to single-stranded DNA (ssDNA), the primers must fit both forward and reverse DNA 




DNA consists of nucleotides and during reading, the DNA polymerases capture the free 
dNTPs to create new DNA sequences.  
 
1.6.1.4 The PCR cycles 
1. Denaturation. Upon heating, the dsDNA is  
denaturated and divided into (ssDNA). The DNA 
polymerase will not get affected of the heat, since it 
is heat-resistant. 
2. Hybridization. The temperature drops, and the 
primers anneal to complementary nucleotides in the 
ssDNA.  
3. Elongation of DNA. The temperature adapts to an 
optimal working temperature for the DNA 
polymerase, which makes it possible to build DNA 
copies from dNTPs. 
These 3 steps are repeated for 30-50 cycles, and DNA is 
amplified for each cycle. 
4. Detection. The PCR products (amplicons) can be 
detected with different techniques 
a. Size separation via gel electrophoresis (not further 
discussed here). 
b. Signals from sequence-specific, reporter-labeled 
probes. In a real-time PCR, a probe will hybridize 
the ssDNA in step 2 above. The probe consists of 
complementary nucleotides placed between the 
nucleotides for the forward and reverse primer, a 
fluorescent reporter dye in its 5´end and a 
quencher in its 3´end. The quencher´s function is 
to prevent the reporter from sending a fluorescent 
signal until the DNA polymerase arrives and 
cleaves the probe. When cleaved, the signal is 
sent, and the number of signals is directly related 




1.6.2 Nested PCR 
Since primers bind to complementary nucleotides 
throughout the whole DNA, incorrect DNA sequences 
may be amplified. To avoid this, the amplification can 
be performed in two steps with two different sets of 
primers, consisting of different nucleotide sequences, 
so-called nested PCR (120). The first set of primers - 
outer primers - bind outside the DNA sequence to be 
copied. The second set of primers - inner primers - 
binds more specifically to the requested sequence. The 
specificity of the PCR and the sensitivity of the assay increase. 
 
1.6.3 Enzyme-Linked ImmunoSpot Assay (ELISpot) 
Each antibody targets, and binds specifically to, its unique protein. If a traceable molecule is 
bound to the antibody, the antibody-protein complex can be detected.  
All cell types express their own unique proteins on the cell surface. Protein expression can 
vary if the cell is activated by a stimulus or at rest. With antibodies directed against the cell 
surface proteins, information can be obtained about the cell type and whether the cells are 
activated. These principles are used in various laboratory methods – immunoassays. 
If the presence or amount of proteins already produced is to be analyzed, the classical 
method Enzyme-Linked ImmunoSorbent Assay (ELISA) can be used (121). If the number of 
cells that have an ongoing protein production is to be examined, an ELISpot can be selected 
(122). ELISA will not be further discussed in this thesis. 
Basic principles of immune assays are presented in Figure 5. 
 
1.6.3.1 The procedure of ELISpot 
1. Preparing and coating. The inside of the wells of a culture plate is coated with 
primary antibodies, which bind specifically to a unique cell surface protein secreted 
from activated cells from the cell type to be analyzed. 
2. Activating cells. In the wells, a cell mixture (e.g. a blood sample) is added together 
with a stimulus, (e.g. an antigen) which activates the desired cells.  
3. Cell surface protein excreted. Once activated, cell surface proteins are formed that 
attach to the primary antibodies. 
4. Removing excess cells. The wells are rinsed, and cells that are not bound to the 





5. Labeling remaining cells. New secondary antibodies, directed against the coated 
primary antibodies, are added to the well, followed by a chromogenic substrate (i.e. 
color marker) which attaches to the secondary antibodies. 
6. Detection. The primary-antibody + cell + secondary-antibody + color-marker 
complex can be detected as spot forming cells in an ELISpot reader. 
 
 





2 AIMS OF THE THESIS 
The overarching aim of this thesis was to contribute additional knowledge about DNA 
viruses that cause unexpected events in patients with hematological diseases – mostly 
malignancies – and to evaluate whether it is advisable to continuously screen for these 
viruses. Two papers focused mainly on HAdV, three papers on B19V while the sixth paper 
focused on HHV- 6, BKV and B19V. 
I. Paper [Quantification of adenovirus DNA in unrelated donor hematopoietic stem cell 
transplant recipients] aimed to evaluate the extent to which HAdV DNA is detected in 
patients undergoing HSCT with unrelated donors and whether screening for HAdV 
DNA in peripheral blood, along with routine screening for HCMV, is advisable.  
II. Paper [Evaluation of a surveillance strategy for early detection of adenovirus by PCR 
of peripheral blood in hematopoietic SCT recipients: incidence and outcome] aimed to 
prospectively evaluate the prevalence of HAdV with means of repeated sampling 
during one year, in patients who had undergone allogeneic HSCT, regardless of donor 
status, and also to evaluate the risk factors that affect the occurrence of HAdV.  
III. Paper [Parvovirus B19 infection in children with acute lymphoblastic leukemia is 
associated with cytopenia resulting in prolonged interruptions of chemotherapy] aimed 
to evaluate the extent to which B19V is prevalent in the bone marrow in children with 
cytopenia where ALL is the baseline diagnosis. We were also interested in whether, 
and if so, B19V affected the patients´ therapy for leukemia. 
IV. Paper [Evaluation of parvovirus B19 infection in children with malignant or 
hematological disorders] aimed to investigate the extent to which B19V DNA is 
detected in bone marrow from children with malignant diagnoses other than ALL, 
whether infection with B19V also affected these patients´ condition and therapy, and if 
screening for B19V would be recommended for episodes of unexpected cytopenia. 
V. Paper [Human parvovirus B19 in pediatric and adult recipients of allogeneic 
hematopoietic stem cell transplantation, 2013] aimed to investigate whether B19V is 
detected in serum during the first year post-HSCT in pediatric and adult patients. 
VI. Paper [Presence of human herpesvirus type 6, polyoma BK virus and parvovirus B19V 
in non-transplanted patients with hematological malignancies and neutropenic fever] 
aimed to investigate the extent to which HHV-6, BKV and B19V are detected in adult 




3 PATIENTS, MATERIALS AND METHODS 
All studies have ethical permissions from the Regional Ethical Review Board in Stockholm. 
3.1 PAPER I [QUANTIFICATION OF ADENOVIRUS DNA IN UNRELATED 
DONOR HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS] 
3.1.1 Patients  
All 40 patients - 27 adults and 13 children – who underwent allogeneic HSCT with matched 
unrelated donors at the Karolinska University Hospital, Huddinge, during January – 
December 2004, as a result of an underlying hematological disease, were included in this 
retrospective study, where DNA from HCMV, HAdV and/or EBV was evaluated for one 
year after the transplantation. Thirty patients (of whom six were children) had a 
hematological malignancy as the underlying diagnosis. One of these patients died before any 
samples were taken. The patients were treated before HSCT, and monitored after HSCT, in 
accordance with the standard programs of Karolinska University Hospital, Huddinge (123). 
All patients underwent T cell depletion in vivo before HSCT, with either anti-thymocyte 
globulin (ATG) or alemtuzumab. 
 
3.1.2 Sample collection 
According to the clinical routines, all patients were screened for the presence of HCMV DNA 
after HSCT at least once a week for 12 weeks, followed by scheduled controls approximately 
6, 9 and 12 months after HSCT. If an infection was suspected, analyses for DNA from 
HCMV, HAdV and/or EBV were performed immediately. To exclude asymptomatic viremia 
in patients not controlled for DNA from HAdV or EBV, three blood samples per patient, 
from the beginning, mid and end of the year, were tested retrospectively. 
 
3.1.3 Methods 
DNA for the viruses was analyzed with quantitative PCR (qPCR) at the Department of 
Clinical Virology, Karolinska University Hospital, where HCMV and EBV were analyzed 
according to applicable laboratory standard. Initially, the presence of HCMV DNA was 
quantified in leukocytes, but during the final three months of the study, the method was 
changed to whole blood analysis. Plasma or serum was used for assays for EBV DNA, and 
serum was used for HAdV DNA. The qPCR assay for detection of HAdV DNA was based on 
amplification of a conserved region of the HAdV hexon (124). The template was 
supplemented with a newly designed probe to minimize mismatch between nucleotides in 
HAdV subgroup C and the PCR amplicon. The sequence of the probe is reported in this 
paper. Clinical data were obtained from the patients´ medical records. 
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3.2 PAPER II [EVALUATION OF A SURVEILLANCE STRATEGY FOR EARLY 
DETECTION OF ADENOVIRUS BY PCR OF PERIPHERAL BLOOD IN 
HEMATOPOIETIC SCT RECIPIENTS: INCIDENCE AND OUTCOME] AND 
PAPER V [HUMAN PARVOVIRUS B19 IN PEDIATRIC AND ADULT 
RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL 
TRANSPLANTATION] 
3.2.1 Patients 
A total of 97 patients - 77 adults and 20 children – out of 1013 patients who underwent 
allogeneic HSCT, with matched unrelated or related donors, at the Karolinska University 
Hospital, Huddinge and Sahlgrenska University Hospital, Gothenburg, during a period for 1.5 
years (March 2006 – September 2007), were included in a prospective study. 
The patients were treated before HSCT, and monitored after HSCT, in accordance with the 
standard programs of Karolinska University Hospital, Huddinge and Sahlgrenska University, 
Gothenburg (123). T cell depletion in vivo were performed in 47 adults and 15 children 
before HSCT, with either anti-thymocyte globulin (ATG) or alemtuzumab.  
 
3.2.2 Sample collection 
According to the HCMV monitoring program, all patients were screened for the presence of 
HCMV DNA, and for this study simultaneously for HAdV DNA and B19V, at least once a 
week for 9 weeks after HSCT. Thereafter, scheduled analyses were performed approximately 
around 6, 9 and 12 months after HSCT. If infection was suspected, DNA analyses were 
performed immediately. 
 
3.2.3 Methods, paper II 
DNA for HAdV was analyzed in plasma with the same qPCR method as described in paper I, 
at the Department of Clinical Virology, Karolinska University Hospital. Clinical data were 
obtained from the patients´ medical records. 
For twelve randomly selected adult patients, a supplemental ELISpot assay was performed to 
evaluate the presence of HAdV-specific T cells. Here, the method is briefly described: 
Day 1, 96-well culture plates were prepared and coated with antihuman IFN- 
monoclonal antibodies in order to detect cells with IFN- release, here T cells. 
Day 2, PBMCs, isolated from blood samples, together with a suspension of HAdV 
antigen, were added to the wells. 
 
3 Four patients were excluded as a result of too few samples (< 5). 
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Day 3, spot-forming cells were detected with an ELISpot reader by the addition of 
biotinylated4 anti-IFN- monoclonal antibodies followed by a color substrate. 
The more detailed protocol with information on the type of monoclonal antibodies, 
substrates, manufacturing companies, etc. is presented in Paper II. 
Risk factors for HAdV infection were evaluated statistically with a multiple logistic 
regression model.  
 
3.2.4 Methods, paper V 
DNA for B19V was analyzed in serum with a qPCR (125) at the Department of Clinical 
Virology, Karolinska University Hospital. 
 
 
3.3 PAPER III [PARVOVIRUS B19 INFECTION IN CHILDREN WITH ACUTE 
LYMPHOBLASTIC LEUKEMIA IS ASSOCIATED WITH CYTOPENIA 
RESULTING IN PROLONGED INTERRUPTIONS OF CHEMOTHERAPY] 
AND PAPER IV [EVALUATION OF PARVOVIRUS B19 INFECTION IN 
CHILDREN WITH MALIGNANT OR HEMATOLOGICAL DISORDERS] 
3.3.1 Patients 
A total of 240 children underwent investigations, for proven or suspected malignancies, at the 
Pediatric Oncology Unit, Karolinska Hospital, Stockholm, during a period for 5.5 years 
(1995-2000). Paper III includes 117 children with ALL, and paper IV includes 123 children 
with hematological diseases, other than ALL, and children with solid tumors – primarily 
neuroblastoma and sarcoma.  
 
3.3.2 Sample collection 
According to the clinical routines, bone marrow from the patients was analyzed when 
malignancy occurred or was suspected. Retrospectively, samples not excluded on technical or 
logistic grounds, were analyzed to investigate the presence of B19V DNA.  
 
 




All bone marrow samples were analyzed with a qualitative nested PCR representing the non-
structural NS protein of B19V (126). Samples positive for the NS protein were further 
analyzed in our group with qPCR (125) performed at the Department of Clinical Virology, 
Karolinska University Hospital. In some cases, the samples had been thawed and frozen on 
several occasions, making it difficult to replicate a positive result from the nested PCR. In 
other cases, the samples contained so much B19V DNA that they had to be diluted several 
times. In those patients where only one of several samples was positive on the nested PCR, 
all samples were re-analyzed in the more sensitive qPCR. In some cases, B19V DNA was 
also detected in some of these samples. All samples that tested positive for B19V DNA in 
either the nested PCR or the qPCR were included in the final assay. Clinical data were 
obtained from the patients´ medical records, and in paper II also from the Nordic Childhood 
Leukemia registry (NCLR). 
In paper III several statistical analyses were performed to evaluate if the results could be 
generally valid. Patients with the presence of B19V DNA were compared to patients without 
B19V DNA. To evaluate how B19V was linked to age and affected the number of days 
without treatment, the Mann-Whitney U-test was used. The association of B19V to age at 
diagnosis, gender, treatment protocol and possible delays in therapy, was evaluated using a 
multivariable linear regression model. To analyze if the need for extra bone marrow 
examinations and extra blood transfusions was limited to only the relatively few patients 
diagnosed with B19V DNA, a logistic and Poisson regression with exact estimates was used. 
 
 
3.4 PAPER VI [PRESENCE OF HUMAN HERPESVIRUS TYPE 6, POLYOMA BK 
VIRUS AND PARVOVIRUS B19V IN NON-TRANSPLANTED PATIENTS 
WITH HEMATOLOGICAL MALIGNANCIES AND NEUTROPENIC FEVER] 
3.4.1 Patients 
A total of 79 adult non-transplanted patients with different hematological malignancies, who 
were treated at the Karolinska University Hospital, Stockholm, and had at least one episode 
of neutropenic fever during a period for 2 years (February 2013 – February 2015) were 
included in the study.  
 
3.4.2 Sample collection 
According to the clinical routines, blood samples were collected when the patient arrived at 





Quantification of HHV-6A or 6B (127) and B19V (125) DNA have been previously 
described. For analysis of  BKV DNA the commercial BKV ELITe MGB ® Kit was used 
(128). All analyzes were according to the applicable laboratory standard, at the Department of 
Clinical Microbiology, Karolinska University Hospital.  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I [QUANTIFICATION OF ADENOVIRUS DNA IN UNRELATED 
DONOR HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS] AND 
PAPER II [EVALUATION OF A SURVEILLANCE STRATEGY FOR EARLY 
DETECTION OF ADENOVIRUS BY PCR OF PERIPHERAL BLOOD IN 
HEMATOPOIETIC SCT RECIPIENTS: INCIDENCE AND OUTCOME]  
Infections with human HAdVs are not uncommon in patients undergoing HSCT  
(4, 129-131). When the samples were collected for the first study, the Department of Clinical 
Virology, Karolinska University Hospital in Huddinge, had just launched the PCR assay for 
HAdV DNA. 
 
4.1.1 Papers I and II 
PCR. The specificity of PCR depends on how unique the gene sequence to be analyzed is and 
how well the method's primers and probes are designed. In the first study a newly designed 
probe was used to minimize mismatch between nucleotides in HAdV subgroup C and the 
PCR amplicon. At the time for the first study, there were no accepted limits for when viral 
DNA loads were “high”, but we considered > 10,000 copies/mL as "high". 
When the presence of viral DNA is analyzed by PCR, only specific DNA sequences are 
searched, i.e. the entire genome is not searched for. It may be unclear if the DNA sequence 
sought comes from a viable virus or if viral residues are captured. Low levels of viral DNA 
detected in blood can also be derived from latent infections. This means that DNA detected 
by PCR does not automatically indicate an ongoing infection. An evaluation of the patient's 
general condition must always be included in the assessment. The general condition of all 
patients with high viral load was evaluated using medical records. 
 
4.1.1.1 Presence of HAdV DNA 
There is no effective treatment for HAdV, but it may still be important to diagnose the virus, 
not for the treatment itself but to rule out other pathogens. In the first study, with patients 
undergoing HSCT with matched unrelated donors, we found HAdV DNA at least on one 
occasion in 6 of 39 (15%) patients tested. For comparison, the presence of HCMV and EBV 
viremia was also evaluated, and according to previous studies, high loads of DNA from 
HCMV and EBV are associated with morbidity and mortality.  
For 27 of 29 patients tested – with underlying hematological malignancies – DNA from 
HAdV, HCMV and/or EBV was detected. High DNA loads (> 10,000 copies/mL) from 
either of the viruses were detected in 11 patients, of whom 8 died in the first year after HSCT. 
Three of the deceased patients had high levels of HAdV DNA and in at least two patients, 
infection with HAdV was considered to contribute to the fatal outcome. High levels of viral 
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DNA were not detected in any of the 10 patients with a non-malignant hematological 
diagnosis.  
Although three samples per patient were retrospectively analyzed from patients without 
symptoms of HAdV infection, and no DNA was present, it was unclear whether transient 
asymptomatic viremia could occur, which the patient himself cured. This, together with the 
fact that high levels of HAdV DNA appeared to be associated with serious or fatal outcomes, 
led to the initiation of study 2. 
In the second study two years later, we found that in patients undergoing HSCT with 
unrelated donors, HAdV DNA in blood could be detected at least on one occasion in 3 of 59 
(5%) patients tested. In the total study population of 97 participants, HAdV DNA was present 
in 5 patients. None of them had high viral DNA loads (> 10.000 copies/mL) of HAdV. None 
of the patients developed symptoms associated with HAdV. 
 
Table 3. Comparison between positive cases in study 1 and study 2 
 
Abbreviations: MDS: Myelodysplastic syndrome, NHL: Non-Hodgkin lymphoma, ALL: Acute lymphoblastic 
leukemia, CML: Chronic myeloid leukemia, SAA: severe anaplastic anemia, BM: Bone marrow, PBSC: 
Peripheral blood stem cells, MC: Myeloablative conditioning, RIC: Reduced intensity conditioning, lc: 




It is interesting that two studies, conducted relatively closely in time, in which patients 
followed the same treatment protocol and the same methods were used, differed regarding the 
presence of HAdV DNA. We do not know what caused the differences, but one explanation 
may be that the number of participants in both studies was too small to cover the normal 
different individual variations that occur in people. Alternatively, the initial hematological 
diagnoses were too heterogeneous, and the number of patients with each diagnosis too few, 
for the results to be representative. A total of 8 different serotypes from species A, B1, B2, C 
were present in the studies - none of them uncommon in immunocompromised patients, see 
Table 2. None of the studies considered co-infections with bacteria or fungi. One conclusion, 
however, is that high levels of DNA from HAdV, CMV or EBV are associated with fatal 
outcome. 
 
4.1.1.2 Risk factors 
In the second study with a total of 97 patients, 15 of 84 (18%) patients with an underlying 
hematological malignancy were diagnosed with myelodysplastic syndrome (MDS). Four of 
these patients presented HAdV DNA in blood, and in two of these, bone marrow was the 
source of stem cells.  
Risk factors for the development of HAdV infection have previously been reported to be low 
age, unrelated donors, total body irradiation, donor HAdV antibodies, in vitro or in vivo T cell 
depletion. In a large study, the virus was isolated exclusively in recipients of T cell-depleted 
grafts (132). In our second study, statistical analysis concluded that the underlying diagnosis 
and type of graft – MDS and bone marrow, respectively – were two independent significant 
risk factors for presenting HAdV DNAemia. Factors that did not increase the risk of HAdV 
infection were the type of preconditioning, in vivo T cell-depletion, TBI, unrelated donors 
and GvHD. A statistical analysis of risk factors was never done in the first study, partly 
because the number of participants was low. When the risk factors MDS and bone marrow 
had been determined, a comparison was made with the first study to see the impact of these 
factors: 
• MDS. In the first study, 6 of 30 (20%) patients with hematological malignancies were 
diagnosed with MDS, of which 5 died. One of the deceased patients received stem 
cells from bone marrow and the DNA loads of HAdV as well as EBV were high. The 
other patients with MDS received PBSC, and in 2 of the deceased, large amounts of 
DNA from HCMV and EBV were detected in blood. DNA from HAdV was not 
present. However, MDS is a heterogeneous diagnosis with many subtypes, which 
were not taken into account when evaluating risk factors. 
• Bone marrow. In the first study, 5 of 30 (17%) patients with underlying hematological 
malignancies received bone marrow as graft. In 3 out of 5 patients, high loads of viral 
DNA were detected in blood. All three died. In addition to the patient with MDS, as 
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mentioned above, the other two patients with diagnoses other than MDS presented 
high viral DNA loads of HAdV and HCMV, respectively, in blood.  
It is important to remember that discussions about risks are usually about the group, not about 
the individual, and risk factors are events that involve increased risk. The absence of one or 
more risk factors does not necessarily mean that the risk does not exist. In medicine, risk 
factors are based on current knowledge. New knowledge is constantly being added. Each 
patient must always be evaluated individually. 
 
4.1.1.3 Screening.  
None of the studies provided a basis for the introduction of HAdV DNA screening in blood 
post-HSCT, but analysis of HAdV DNA in blood was considered valuable to exclude 
possible infections in patients who do not respond as expected to the treatment given after 
HSCT. 
 
4.1.1.4 HAdV specific T cells 
HAdV-specific T cells develop during childhood and are thought to have a cross-reactivity 
between different serotypes of HAdV. Since the patient's own immune system is suppressed, 
it is mainly the presence of the donor's HAdV-specific T cells that is of interest here. With 
ELISpot, the presence of HAdV-specific T cells was analyzed in twelve randomly selected 
patients. In parallel a chimeric analysis for mature T cells was performed, to determine the 
establishment of the graft. Unfortunately, none of the patients in whom HAdV DNA was 
detected were included. The group was heterogeneous with different hematological 
diagnoses, both related and unrelated donors, both T cells-depleted and not T cells-depleted, 
myeloablative conditioning (MC) and reduced intensity conditioning (RIC), and both PBSC 
and bone marrow as grafts. The results are presented below in Table 4, and it is difficult to 
draw any other conclusions than that HAdV-specific T cells were present in 7 of 12 patients. 
 
4.1.1.5 Clinical recommendations for HAdV 
In 2011, the fourth European Conference of Infections in Leukemia (ECIL-4) recommended 
weekly monitoring with qPCR of HAdV in patients with at least one risk factor. Risk factors 
for children and adults are unrelated HSCT with a cord blood graft, severe graft-versus-host 
disease and lymphopenia. Additional risk factors for adults are treatment with alemtuzumab, 
and for children, T cell depletion associated with the HSCT. Generally, children have an 
increased risk of HAdV infections (133).  
Papers I and II are included in the reference list of the ECIL-4 guideline, but the risk factors 
from Paper II were not taken into consideration. 
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Table 4. Relations between patients and results from ELISpot and chimerism. 
 
Abbreviations: AML: Acute myeloid leukemia, Lymph: lymphoma, MDS: Myelodysplastic syndrome, ALL: 
Acute lymphoblastic leukemia, MUD: Matched unrelated donor, BM: Bone marrow, PBSC: Peripheral blood 
stem cells, MC: Myeloablative conditioning, RIC: Reduced intensity conditioning, NA: Not analyzed. 
Cut off value for ELISpot confirming the presence of HAdV specific T cells is 20 spots or 
more. Chimerism status is an analysis of the proportion of stem cells derived from the 
recipient and donor, respectively. The table shows the chimerism of the donor. 
 
 
4.2 PAPER III [PARVOVIRUS B19 INFECTION IN CHILDREN WITH ACUTE 
LYMPHOBLASTIC LEUKEMIA IS ASSOCIATED WITH CYTOPENIA 
RESULTING IN PROLONGED INTERRUPTIONS OF CHEMOTHERAPY], 
PAPER IV [EVALUATION OF PARVOVIRUS B19 INFECTION IN CHILDREN 
WITH MALIGNANT OR HEMATOLOGICAL DISORDERS] AND PAPER V 
[HUMAN PARVOVIRUS B19 IN PEDIATRIC AND ADULT RECIPIENTS OF 
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION] 
It has been shown that B19V DNA is present in children with hematological malignancies, 
i.e. during the so-called maintenance treatment, (134-137) and also in other malignancies 
(138, 139) and is connected to increased need for transfusions, extra bone marrow tests and 
also interruptions in the ongoing chemotherapy. In immunocompetent individuals without 
malignancies, bone marrow persistence of B19V may exist, but is not common after the 
primary infection (140, 141).  
 
4.2.1 Papers III and IV 
4.2.1.1 PCR 
The analysis of the extensive material (726 bone marrow samples) started with nested 
qualitative PCR with sequences from the essential protein NS1 as primer. When B19V DNA 
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was detected in a patient, complementary analysis was performed for all samples from that 
patient, using a more sensitive qPCR method (125). A clinical evaluation using medical 
records was performed for all patients who presented B19V DNA in bone marrow. 
 
4.2.1.2 Presence of B19V DNA 
In studies 3 and 4 bone marrow samples from 240 children, collected under 5.5 years were 
tested in retrospective. In total, B19V DNA was detected in 27 patients. According to the 
medical records only one patient had symptoms typical of B19V infection. No analysis was 
performed to evaluate the presence of B19V DNA in peripheral blood. 
The most common diagnosis for bone marrow sampling was ALL and the results are 
presented in study 3. Other diagnoses for bone marrow sampling were AML, NHL, other 
hematological malignant and non-malignant disorders as well as solid tumors such as 
neuroblastoma and sarcoma, which are presented in study 4. The number of patients within 
each diagnosis and the presence of B19V DNA are presented in Table 5. 
 
Table 5. Patients positive for B19V DNA 
 
Abbreviations: ALL: Acute lymphoblastic leukemia, AML: Acute myeloid leukemia, NHL: Non-Hodgkin 
lymphoma, MDS: Myelodysplastic syndrome. 
 
The treatment protocols for ALL have varied over the years, but generally after a thorough 
examination of the disease, an induction phase begins with high-dose cytostatic and 
cortisone, currently for about a month, followed by maintenance treatment with varying 
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chemotherapies for about 2.5 years (142). Compared to the induction phase, the maintenance 
phase is less toxic and severe cytopenia is not expected. 
In the group with ALL, B19V DNA was detected in seven patients during maintenance 
therapy. A statistically significant association could be found between the presence of viral 
DNA and an increased number of episodes of unexpected cytopenia requiring erythrocyte- 
and/or thrombocyte infusions and more days of treatment discontinuation, compared with 
patients without B19V DNA in bone marrow. In four of these patients, episodes of cytopenia 
were so severe that relapse in ALL was suspected. The viral load was higher in patients in the 
maintenance phase compared to the other patients. However, both the underlying disease and 
the toxic effect of chemotherapy can affect the number of cells in the bone marrow. Because 
the number of cells was not counted, it is difficult to draw any conclusions based on viral 
load.  
No statistically significant conclusions could be drawn for the 6 patients who were in the 
diagnosis and induction phase, nor for the 5 patients who had completed their chemotherapy.  
The non-ALL group included heterogeneous diagnoses that require different therapies. In 
eight of nine patients, B19V DNA was detected in the first bone marrow sample, which was 
performed as part of the diagnostic examination. Because bone marrow punctures are 
invasive, no further sampling was performed for the majority when the diagnosis was made, 
unless it was absolutely necessary. None of the patients were immunosuppressed and none 
had received any previous blood products. B19V serology was not examined. During the 
following six months after diagnosis, seven of the patients had several episodes of fever and 
prolonged transfusion-requiring cytopenia. Complementary bone marrow punctures were 
performed in four patients with hematological malignancies, where B19V DNA was present 
for up to two years. Because the number of underlying diagnoses in the non-ALL group was 
broad-spectrum, statistical evaluation was not possible. 
 
4.2.1.3 Serology 
In 2002 Heegaard et al, showed that children with ALL could seroconvert with respect to 
B19V, both from IgG-negative to IgG-positive as well as the opposite, i.e. losing the 
antibodies. Upon conversing to IgG-positive, B19V DNA was detected in peripheral blood, 
and the infection resulted in anemia 
and thrombocytopenia (143).  
In the first study, serology testing 
was performed for 38 patients 
with ALL. The limited 
serological evaluation showed 
that B19V IgG was present in 15 
patients where B19V DNA could 
Table 6. Serology for patients in study 3. 
 
 41 
not be detected in bone marrow, see Table 6. The result is interesting and may indicate that 
the immunogenic effect of B19V remains in some patients with ALL, but the number of 
patients in this study is too small to draw such conclusions. 
 
4.2.2 Paper V 
To evaluate whether B19V infection occurs in patients undergoing HSCT, 97 patients (77 
adults, 20 children) from study 2 were analyzed by qPCR for the possible presence of B19V 
DNA in peripheral blood. Samples were collected weekly for the first nine weeks post-HSCT 
and then on return visits approximately week 12, 26 and 52.  
B19V DNA was detected in two adults and one child undergoing HSCT with a matched 
unrelated donor (MUD) with peripheral blood stem cells (PBSC) and T cell depletion. When 
B19V DNA was detected, the child had fever, but none of the adults reported any symptoms. 
This was consistent with previous observations where a low prevalence of B19V infections 
has been reported post-HSCT (144). 
 
4.2.3 Clinical recommendations 
From an academic point of view, it is interesting to know whether the presence of B19V is a 
primary or reactivated infection, which the studies 3 and 4 could not determine. From a 
clinical perspective, it is more important to know if infectious B19V is present, and that the 
methods used to detect the virus are reliable.  
If unexpected cytopenia occurs in a child with hematological malignancy, the current clinical 
practice at Karolinska University Hospital is, based on several studies - our studies included, 
that blood samples and even bone marrow - if available – are checked for presence of B19V 
DNA. 
For children with hematological malignancies, there is no exact viral DNA load of B19V 
indicating a clinically relevant viremia. The assessment of a threshold value is also 
complicated by the fact that the patients´ immune status are affected by the treatment and the 
underlying disease. For comparison, it can be stated that in the acute phase, and before the 
onset of symptoms, the level of B19V DNA in serum in an immunocompetent individual can 
reach > 1x1010 copies/mL (55). The level of viral DNA decreases quite rapidly, but a low 
level can remain for several years as a sign of a persistent infection (145). 
At what B19V DNA level the infection should be considered as “recent” or “past” is 
discussed, and a suggestion is a cut-off level of about 1x104 copies/mL. If there is uncertainty 
regarding the interpretation of levels around 1x104 copies/mL, it is recommended that the 
analysis be supplemented with serology (146). It is not possible to find information in the 
literature on how different levels of B19V DNA in bone marrow should be interpreted. 
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In adults with hematological malignancies or who have undergone HSCT, and where 
unexpected cytopenia occur, there is currently no general protocol for B19V DNA testing. 
 
 
4.3 PAPER VI [PRESENCE OF HUMAN HERPESVIRUS TYPE 6, POLYOMA BK 
VIRUS AND PARVOVIRUS B19V IN NON-TRANSPLANTED PATIENTS 
WITH HEMATOLOGICAL MALIGNANCIES AND NEUTROPENIC FEVER] 
Paper I, II and V include adults who were immunosuppressed as a result of HSCT. Paper VI 
includes adults with hematological malignancies, who have not undergone HSCT, and in 
whom immunosuppression was due to chemotherapy. Because the conclusions in the 
literature are not entirely consistent regarding the prevalence of HHV-6A, 6B and BKV DNA 
in blood in adult immunosuppressed patients not undergoing HSCT, the presence of these 
viruses was studied when patients were diagnosed with neutropenic fever. As neutropenia 
occurred, analyses of B19V DNA in blood were included.  
None of the patients presented DNA from HHV-6A. In 14 of 79 (18%) patients, DNA from 
any of the other viruses was present, see Table 7. One patient was diagnosed with “fever of 
unknown origin” (FUO). For the other patients, alternative explanations for the fever were 
found.  
A high viral load in blood of HHV-6B DNA (2,4 x 105 copies/mL) was detected in a patient 
with a blood neutrophil count of <0.1x109/L. This may indicate chromosomally integrated 
HHV-6B DNA rather than viral reactivation.  
Because analyzes were not performed on the patients´ bone marrow, this study does not 
clarify whether HHV-6B, BKV or B19V in any way contributed to these patients´ 
neutropenia. Paper III and IV presented B19V-associated cytopenia in children undergoing 
chemotherapy and BKV may cause cytopenia in kidney-transplant recipients (147). Whether 
infectious B19V and/or HHV-6B is present in bone marrow of adults undergoing 
chemotherapy is less well known. There are case reports in the literature on infectious virus, 
but it is difficult to find studies evaluating infectious B19V or HHV-6B in bone marrow. 
Whether this is a consequence of the lack of findings not being considered interesting, or the 
fact that studies have not been carried out, is unclear.  
On one hand, it is a pity that the bone marrow was not tested in this study. On the other hand, 
it is doubtful to perform bone marrow puncture, an invasive method, on patients with 
neutropenic fever, unless the results of the tests are essential for the patient's treatment. There 
is currently no general recommendation for bone marrow analysis when neutropenic fever 
occurs in adult patients undergoing chemotherapy. 
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  Table 7. Viral DNA in adult patients with 
non-transplanted hematological 
malignancies. 
Abbreviations: ALL: Acute lymphoblastic leukemia,  




5 CONCLUSIONS AND FUTURE PERSPECTIVES 
The aim of these studies was to understand the prevalence of HAdV and B19V infections in 
different groups of immunosuppressed patients, and whether established screening programs 
for these infections, as well as for infections with HHV-6A, 6B and BKV, may be of clinical 
value.  
 
Diagnosis of viral infections 
The proportion of patients with HAdV infection in our material was relatively small, 
compared to the literature, and asymptomatic infections did not occur. On the other hand, 
HAdV DNA loads >15,000 copies/mL in blood were associated with morbidity and 
mortality. Findings of B19V in bone marrow from children undergoing treatment for ALL 
were associated with discontinuation of treatment, leading to prolonged chemotherapy. 
Neither B19V, HHV-6A, 6B nor BKV was common in the blood of adult patients with 
hematological malignancies who were immunosuppressed due to chemotherapy. Overall, 
general screening for these viruses, in the patient groups presented, does not seem to be 
indicated according to these studies. However, testing for HAdV should be performed 
generously when unexpected symptoms occur, even if they are not associated with common 
signs of the virus infection. B19V infection is almost always linked to some form of 
cytopenia, and if unexpected cytopenia occurs in children undergoing chemotherapy, B19V 
infection should be ruled out. 
While analyzing the present studies, the challenges that many clinicians face also emerged. 
One of the challenges is to understand if unexpected symptoms are due to the underlying 
disease or an ongoing therapy, or should be related to pathogens - viruses, bacteria or fungi. 
At present, there is no rapid general analysis that can determine the type of pathogen that 
causes an infection. This can result in excessive antibiotic use and subsequent risk of 
antibiotic resistance. However, each group of pathogens, bacteria, viruses or fungi, must be 
tested separately, based on the clinical assessment. Another challenge is to identify if an 
infection is systemic or local - should samples be taken from blood, tissue or both? 
Reactivated infections with B19V and HAdV often begin at a tissue site and cannot always 
be detected in blood until the infection becomes apparent and symptoms, sometimes severe, 
have occurred. Yet another challenge, when the type of pathogen is to be determined, e.g. a 
virus, is to pre-define which virus to test for since each test is specific. Molecular methods are 
relatively fast and for respiratory viruses there are methods for multi-testing, i.e. one can test 
for several viruses simultaneously. However, tests for blood-borne viruses and viruses in 
tissues are still based on the clinician deciding in advance which virus to test for. If the 
clinician assessed the diagnosis correctly, the quantitative value of the viral load may be 
indicative. However, if the assessment was incorrect regarding which virus to test for, the 
pre-selected PCR will not provide further information. This means that a patient may have a 
fulminant viral infection, but if the initial assessment (guess) regarding the virus was 
incorrect, the analysis will have no major value. 
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Targeted microbiological examinations to cover unclear or rare pathogens are available 
today, but are not routinely used in the clinic. For example, there are possibilities to analyze 
all nucleic acids in a sample material by so-called metagenomics, and then compare any non-
human sequences with databases of different pathogens. The method sounds simple, but 
requires skilled bioinformatics and clinical understanding, as large amounts of "noise" are 
often generated. Convenient and cost-reduced assays for clinical use are thus highly needed. 
 
The patient´s immune system 
Although the methods of analysis are becoming more advanced, there is a need to increase 
the understanding of how the human immune system reacts to various infections. This is 
because it is unclear why some patients seem to suffer more from viral infections than others, 
even though the external conditions seem to be the same.  
Perhaps at some point in the future, the individual will be able to get an accurate description 
of their own immune system - much in the same way that an individual's e.g. blood type can 
be determined today. Perhaps it will also be clarified why some individuals remain 
asymptomatic, while others can become very ill from the same pathogen. With such 
knowledge, different individuals can take different measures to protect themselves against 
infection, sampling and treatment would be individually focused and perhaps thus more 
effective and contribute to reduced morbidity.  
 
Antiviral therapies 
According to the recommendations of ECIL-4, prophylactic treatment of HAdV is not 
recommended. The document points out T cell depletion as one of the risk factors for HAdV 
infection. More risk factors are stated in the document but are not discussed further here. For 
patients with viremia and at least one risk factor, preemptive treatment with cidofovir, a 
cytidine5 analogue, is recommended, even if the viremia does not appear to be clinically 
significant. When an infection with HAdV occurs, it is recommended to reduce the 
immunosuppressive treatment, if possible. If this is not possible, or if the infection persists, 
treatment with cidofovir is recommended. The document states that no clinical trials have 
been performed that clearly support the effect of cidofovir as an antiviral medication. 
Treatment with donor-derived HAdV-specific T cells are also discussed, which should 
primarily be seen as an experimental treatment (133). 
There are no specific antiviral drugs for the treatment of B19V infection. However, if a 
severe B19V infection is diagnosed, intravenously administered immunoglobulin 
intravenously (IVIG) is recommended. Neutralizing antibodies against B19V are a natural 
component of the IVIG preparation and can effectively lower the B19V load in 
 
5 Cytidine is a nucleoside, i.e. a cytosine molecule linked to the sugar molecule ribose. 
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immunosuppressed patients (55). A vaccine against B19V, consisting of viral capsid proteins, 
has been tested in clinical trials. Neutralizing antibodies to VP1 and VP2 were detected as a 
result of the vaccine (148, 149). No evaluation has been made as to whether the vaccine can 
prevent reactivation of B19V infection. However, the trial was discontinued due to 
unexplained cutaneous events (148, 150).  
Regarding infection with BKV and based on current data, the Swedish reference group for 
antiviral therapy (RAV) does not recommend cidofovir as standard treatment for BKV. RAV 
states, however, that it cannot be ruled out that a certain effect may exist. Attempts have been 
made to treat BKV with IVIG. The results have been contradictory, and IVIG cannot be 
recommended as a treatment (151). An ongoing phase 2 clinical trial is testing whether 
human monoclonal antibodies can neutralize all four genotypes of BKV. The first patient was 
included in August 2020 (152). 
When HHV-6 is reactivated, it occurs mainly post-HSCT and symptoms associated are e.g. 
fever and rash, myelosuppression, GvHD and even pneumonitis; conditions that cause 
increased morbidity and mortality. There is currently no specific treatment for HHV-6 
viremia. Immunotherapy with HHV-6-specific T cells has been tested in small studies. The 
most serious clinical complication of HHV-6B is encephalitis, which is a major contributor to 
increased morbidity and mortality (153). HHV-6-induced encephalitis, or its treatment, will 
not be further discussed here. Finally, increased knowledge about the clinical significance of 
the presence of viral DNA in the blood and/or bone marrow of immunosuppressed patients 
with hematological malignancies will be useful tools in future therapies. Hopefully in the 
future there will also be a wide range of new antiviral compounds. Another hope is that the 
treatment arsenal will also be expanded with effective adoptive cell therapy against viral 
infections. Whether such interventions, as mentioned above, will be used as prophylactic, 
preemptive or symptomatic treatment, there will be an urgent need to monitor viral loads. The 
current thesis can thus inform the field about clinically relevant viral infections in selected 












6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Virusinfektioner kan ge allvarliga, och t.o.m. livshotande, tillstånd hos patienter som 
genomgår transplantation med blodstamceller, s.k. hematopoetisk stamcellstransplantation 
(HSCT). Detsamma gäller för många patienter som erhåller behandling till följd av malign6 
blodsjukdom. Både HSCT och behandlingarna påverkar och försämrar patienternas 
immunförsvar, vilket innebär att de har en ökad risk för att få olika infektioner, t.ex. 
virusinfektioner.  
Olika typer av virus innehåller ett för virustypen specifikt arvsanlag – här DNA. Med hjälp av 
diagnostiska metoder, exempelvis kvantitativ PCR, går det att analysera om virus-DNA finns 
i exempelvis ett blodprov. Med hjälp av metoden går det även att bedöma hur mycket DNA 
som finns, och därmed beräkna hur mycket virus som finns. 
Målet med denna avhandling, har varit att utvärdera i vilken omfattning vissa virus bidrar till 
att försämra prognosen för de patienter som nämns ovan. 
 
HAdV är ett virus som kan ge svår sjukdom hos patienter med nedsatt immunförsvar. I 
delstudie I utvärderades i efterhand hur mycket DNA från humant adenovirus (HAdV) som 
fanns i blodet hos 40 patienter som genomgått HSCT. Patienterna hade fått stamceller från 
icke-besläktade givare. Eftersom immunsystemets T celler kan störa återhämtningen efter en 
HSCT, hade patienternas T celler tagits bort före HSCT. T celler är dock viktiga för att 
bekämpa virusinfektioner. Hos sex av de 40 (15%) patienterna kunde HAdV DNA påvisas i 
blod, och alla hade symtom av olika slag. En av patienterna hade ca 15 000 DNA-kopior/mL 
blod och även mycket DNA från Epstein-barr virus (EBV). Två patienter hade miljontals 
DNA-kopior/mL blod, och en av dessa hade förutom DNA från HAdV även mycket DNA 
från EBV och cytomegalovirus (HCMV). Samtliga tre patienter avled inom några månader 
efter HSCT. De andra tre patienterna hade låga nivåer av HAdV DNA i blodet. För att 
utesluta att det fanns infektioner, som inte gav symtom (asymtomatiska infektioner), 
analyserades även blod från de patienter som inte uppvisat symtom på virusinfektion. HAdV 
DNA kunde inte hittas hos någon av dessa patienter.  
 
I delstudie II följdes 97 patienter (77 vuxna och 20 barn) som genomgått HSCT. Patienterna 
provtogs regelbundet för att se om de hade DNA från HAdV i blodet. Samma PCR-metod 
användes som i delstudie I. Den här patientgruppen hade fått stamceller från både besläktade 
och icke-besläktade givare. Hos ungefär hälften av patienterna hade T cellerna tagits bort 
innan HSCT genomfördes. DNA från HAdV påvisades i blodet hos fem av 97 patienter  
(5%), och den högsta uppmätta mängden DNA från HAdV var 9 000 DNA-kopior/mL blod.  
Detta resultat var på ett sätt förvånande, med tanke på resultatet från delstudie I, men å andra 
sidan visar det att man inte kan dra långtgående slutsatser från endast en delstudie.  
 
6 Med malign menas elakartad sjukdom, ofta tumörsjukdom av något slag. 
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I den andra delstudien undersöktes även om tolv slumpmässigt utvalda patienter efter HSCT 
hade T celler som specifika kunde angripa HAdV. Ingen av dessa tolv patienter hade DNA 
från HAdV i blodet. Hos sju av patienterna kunde HAdV specifika T celler påvisas, men så 
mycket mer slutsatser än så kunde inte dras.  
 
I delstudie III och IV studerades i vilken omfattning DNA från parvovirus B19 (B19V) 
fanns i benmärg hos barn som undersökts, eller genomgått behandling, för maligna 
sjukdomar. B19V är känt för att bland annat påverka benmärgen och orsaka brist på olika 
blodceller. Analyser gjordes också för att bedöma om viruset försämrat prognosen för att 
tillfriskna.  
 
I delstudie III undersöktes i efterhand samtlig tillgänglig benmärg från 117 barn med 
diagnosen akut lymfoblastisk leukemi (ALL). Behandling mot ALL pågår under flera år, och 
inleds med en tuff s.k. induktionsbehandling där bland annat cellgifter ges under flera veckor. 
Efter det följer flera års s.k. underhållsbehandling, där cellgifter också ges, men i lägre doser. 
Hos arton av de 117 barnen (15%), kunde DNA från B19V påvisas i benmärg. Hos sex barn i 
samband med induktionsbehandlingen, hos sju barn i samband med underhållsbehandlingen 
och hos fem barn efter avslutad behandling. Mängden B19V DNA i benmärg var högst hos 
de barn som genomgick underhållsbehandling. När DNA från B19V fanns i benmärgen såg 
man att det samtidigt var brist på olika celler i blodet. Dessa barn fick fler blodtransfusioner 
jämfört med övriga barn. Ibland hade bristen på blodceller tolkats som att sjukdomen 
förvärrats, eller börjat om igen. Flera av barnen var tvungna att avbryta eller skjuta upp 
behandlingen med cellgifter. Barnens underhållsbehandling påverkades alltså av att det fanns 
DNA från B19V i benmärgen. Endast ett barn hade symtom som kunde kopplas till infektion 
med B19V.  
 
I delstudie IV undersöktes i efterhand benmärg från 123 barn med akut myeloisk leukemi, 
non-Hodgkins lymfom och s.k. solida tumörer7. Benmärg från barn som inte hade malign 
sjukdom, men ändå hade påverkan på blodet, undersöktes också. Inget av de 123 barnen hade 
dåligt immunförsvar. Hos nio av de 123 barnen (7%) hittade man DNA från B19V i 
benmärgen. Sju av barnen hade återkommande feberepisoder och så långvarig brist på 
blodceller att de behövde flera blodtransfusioner. Inget av barnen hade symtom som kunde 
kopplas till infektion med B19V. 
 
I delstudie V undersöktes förekomsten av B19V DNA i blod hos de 97 patienter som ingick i 
delstudie II ovan. Hos tre patienter, ett barn och två vuxna, kunde man hitta DNA från B19V. 
Barnet hade till en början feber, men hos de vuxna fanns inga symtom som kunde kopplas till 
infektion med B19V. Hos samtliga tre patienter försvann B19V DNA spontant. 
 
 
7 Med solida tumörer menas tumörsjukdom som finns någon annanstans än i blodet. 
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I delstudie VI analyserades i efterhand om det fanns DNA från herpesvirus 6A eller 6B 
(HHV-6A, 6B), polyoma BK-virus (BKV) eller B19V i blod hos 79 vuxna, som på grund av 
behandling för malign sjukdom i blodet, hade brist på vissa immunceller (neutropeni) och 
dessutom hade feber. Funderingar fanns om HHV-6A eller 6B, BKV eller B19V kunde vara 
orsaken till själva febern? Ingen av de 79 patienterna hade DNA från HHV-6A. Små mängder 
DNA från B19V fanns hos några få patienter. Hos sex patienter fanns DNA från HHV-6B 
och hos nio patienter fanns DNA från BKV. Hos samtliga 79 patienter, utom en, kunde en 
rimlig förklaring ges till febern, som var en annan än att den skulle vara orsakad av något av 
de virus som analyserats. 
 
Sammantaget är generell screening för HAdV, B19V, BKV eller HHV-6A, 6B inte aktuell 
för de patientgrupper som har studerats här. Om oväntade symtom uppstår hos patienter som 
genomgått HSCT, ska man dock vara generös med att testa om DNA från HAdV finns. 
Infektion med B19V är nästan alltid kopplad till någon form av brist på blodceller, och om 
oväntad brist på blodceller uppträder hos barn som genomgår behandling för malign sjukdom 




During these years I have had the privilege of meeting and working with many wonderful 
people. I am sincerely grateful to each and every one of you, and would like to say a special 
thank you: 
To all patients who participated in the studies. 
To Kristina Broliden, my calm and patient main supervisor with a fantastic ability to always 
find a positive way forward. To Lars Öhrmalm, my co-supervisor as a contribution with his 
ingenuity. To my former co-supervisor Oscar Norbeck, who contributed a lot in the 
beginning. To my former co-supervisor Thomas Tolfvenstam, who is no longer with us, and 
whom we miss a lot. To Carl and Zhibing, who have helped me a lot in my latest work. 
To the rest of the former Broliden group, Mia and Pernilla, who always helped, and kept 
track of us who messed around in the laboratory, Anna with whom I discuss a lot of research, 
Tove, Pauline, Klara, Anne and all other former PhD-students who I had the privilege of 
hanging out with in the lab, Annelie who has always been so kind. A special thank you to 
Michelle, who taught me Asian style, why you should sit near the buffet and with whom I 
spent many philosophical hours - our kioskvältare is not finished yet... Also, a thank you to 
all colleagues in the lab in recent years, Martina, Gabriella, Frideborg… and… there is no 
place to mention you all.  
To Siw, Marianne, Maryam, Maria, Magnus and all the other former colleagues at the 
department of pulmonary diseases for friendship, support and encouragement in the daily 
clinical work. To Jessica, Monika, Annika, Kina, Lena, Anna, Eric, Maria, Liselott, 
Gunilla and everyone else I worked with during the intense, strenuous and educational years 
we moved a hospital. 
To my current colleagues at the Swedish Work Environment Authority - in the corona-team: 
Jenny, Tatjana, Maria, Helene and Björne - whose humor is hard to do without, but what if 
we could have spent our time on other things ... and at my actual unit Ingemar, Ewa, Ulla, 
Christina, Pia, Viveca, I cannot name you all so I say - no one mentioned, no one forgotten - 
with whom I have spent a lot of time in recent years. 
To all my colleagues at various clinics for occupational and environmental medicine - thank 
you for your support. Viruses are just particles, but in a different way ... 
To Britt-Marie because you always believe in me and for the encouragement you give. 
To my friends Daina, Robert, Janne and Malin and all other friends outside the lab, no 
more words need to be said here - you know who you are and what you mean to me.  




1. (ICTV) ICoToV. Virus Taxonomy:2019 Release. University of Alabama at Birmingham: 
International Committee on Taxonomy of Viruses (ICTV). Available from: 
https://talk.ictvonline.org/taxonomy/. 
2. ViralZone. Virus symmetry and T number [Internet]. Lausanne: SIB Swiss Institute of 
Bioinformatics; 2020. Available from: https://viralzone.expasy.org/8577. 
3. Davison AJ, Benkő M, Harrach B. Genetic content and evolution of adenoviruses. J Gen 
Virol. 2003;84(Pt 11):2895-908. 
4. Echavarría M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 
2008;21(4):704-15. 
5. Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin 
Microbiol Rev. 2014;27(3):441-62. 
6. Wiethoff CM, Nemerow GR. Adenovirus membrane penetration: Tickling the tail of a 
sleeping dragon. Virology. 2015;479-480:591-9. 
7. Robinson CM, Seto D, Jones MS, Dyer DW, Chodosh J. Molecular evolution of human 
species D adenoviruses. Infect Genet Evol. 2011;11(6):1208-17. 
8. (NIH)/GenBank NCfBi. HAdV Working Group [Internet].  [updated July, 2019]. Available 
from: http://hadvwg.gmu.edu/. 
9. Seto D, Jones MS, Dyer DW, Chodosh J. Characterizing, typing, and naming human 
adenovirus type 55 in the era of whole genome data. J Clin Virol. 2013;58(4):741-2. 
10. Kosulin K. Intestinal HAdV Infection: Tissue Specificity, Persistence, and Implications for 
Antiviral Therapy. Viruses. 2019;11(9). 
11. Mennechet FJD, Paris O, Ouoba AR, Salazar Arenas S, Sirima SB, Takoudjou Dzomo GR, et 
al. A review of 65 years of human adenovirus seroprevalence. Expert Rev Vaccines. 
2019;18(6):597-613. 
12. de Ory F, Avellón A, Echevarría JE, Sánchez-Seco MP, Trallero G, Cabrerizo M, et al. Viral 
infections of the central nervous system in Spain: a prospective study. J Med Virol. 
2013;85(3):554-62. 
13. Akkaya O, Guvenc HI, Yuksekkaya S, Opus A, Guzelant A, Kaya M, et al. Real-time PCR 
Detection of the Most Common Bacteria and Viruses Causing Meningitis. Clin Lab. 
2017;63(4):827-32. 
14. Chandran B, Hutt-Fletcher L, Arvin A, Campadelli-Fiume G, Mocarski E, Moore P, et al. 
Gammaherpesviruses entry and early events during infection, Chapter 23.  Human 
Herpesviruses: Biology, Therapy, and Immunoprofylaxis: Cambridge University Press; 2007. 
15. Spear PG, Longnecker R. Herpesvirus entry: an update. J Virol. 2003;77(19):10179-85. 
16. Neves M, Marinho-Dias J, Ribeiro J, Sousa H. Epstein-Barr virus strains and variations: 
Geographic or disease-specific variants? J Med Virol. 2017;89(3):373-87. 
17. E X, Meraner P, Lu P, Perreira JM, Aker AM, McDougall WM, et al. OR14I1 is a receptor 
for the human cytomegalovirus pentameric complex and defines viral epithelial cell tropism. 
Proc Natl Acad Sci U S A. 2019;116(14):7043-52. 
18. Shenk T, Stinski M. Human Cytomeaglovirus Genome.  Human Cytomegalovirus, Current 
Topics in Microbiology and Immunology. Berlin Heidelberg: Springer-Verlag; 2008. p. 1-20. 
19. Agut H, Bonnafous P, Gautheret-Dejean A. Update on infections with human herpesviruses 
6A, 6B, and 7. Med Mal Infect. 2017;47(2):83-91. 
 
54 
20. Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, et al. 
Classification of HHV-6A and HHV-6B as distinct viruses. Arch Virol. 2014;159(5):863-70. 
21. Vanarsdall AL, Johnson DC. Human cytomegalovirus entry into cells. Curr Opin Virol. 
2012;2(1):37-42. 
22. Ciferri C, Chandramouli S, Leitner A, Donnarumma D, Cianfrocco MA, Gerrein R, et al. 
Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes 
Reveals Binding Sites for Potently Neutralizing Human Antibodies. PLoS Pathog. 
2015;11(10):e1005230. 
23. Chen J, Longnecker R. Epithelial cell infection by Epstein-Barr virus. FEMS Microbiol Rev. 
2019;43(6):674-83. 
24. Gerna G, Kabanova A, Lilleri D. Human Cytomegalovirus Cell Tropism and Host Cell 
Receptors. Vaccines (Basel). 2019;7(3). 
25. Vanarsdall AL, Pritchard SR, Wisner TW, Liu J, Jardetzky TS, Johnson DC. CD147 
Promotes Entry of Pentamer-Expressing Human Cytomegalovirus into Epithelial and 
Endothelial Cells. mBio. 2018;9(3). 
26. Martinez-Martin N, Marcandalli J, Huang CS, Arthur CP, Perotti M, Foglierini M, et al. An 
Unbiased Screen for Human Cytomegalovirus Identifies Neuropilin-2 as a Central Viral 
Receptor. Cell. 2018;174(5):1158-71 e19. 
27. Dominguez G, Dambaugh TR, Stamey FR, Dewhurst S, Inoue N, Pellett PE. Human 
herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 
6A. J Virol. 1999;73(10):8040-52. 
28. Tang H, Serada S, Kawabata A, Ota M, Hayashi E, Naka T, et al. CD134 is a cellular receptor 
specific for human herpesvirus-6B entry. Proc Natl Acad Sci U S A. 2013;110(22):9096-9. 
29. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular 
receptor for human herpesvirus 6. Cell. 1999;99(7):817-27. 
30. Thorley-Lawson DA. EBV Persistence--Introducing the Virus. Curr Top Microbiol Immunol. 
2015;390(Pt 1):151-209. 
31. Dunmire SK, Verghese PS, Balfour HH, Jr. Primary Epstein-Barr virus infection. J Clin 
Virol. 2018;102:84-92. 
32. Sinzger C, Digel M, Jahn G. Cytomegalovirus Cell Tropism.  Human cytomegalovirus, 
Current Topics in Microbiology and Immunology. Berlin Heidelberg: Springer-Verlag; 2008. 
p. 63-78. 
33. Arbuckle JH, Medveczky MM, Luka J, Hadley SH, Luegmayr A, Ablashi D, et al. The latent 
human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in 
vivo and in vitro. Proc Natl Acad Sci U S A. 2010;107(12):5563-8. 
34. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481-92. 
35. Nikitina E, Larionova I, Choinzonov E, Kzhyshkowska J. Monocytes and Macrophages as 
Viral Targets and Reservoirs. Int J Mol Sci. 2018;19(9). 
36. Hutt-Fletcher LM. Epstein-Barr virus entry. J Virol. 2007;81(15):7825-32. 
37. Cannon MJ, Hyde TB, Schmid DS. Review of cytomegalovirus shedding in bodily fluids and 
relevance to congenital cytomegalovirus infection. Rev Med Virol. 2011;21(4):240-55. 
38. Dioverti MV, Razonable RR. Cytomegalovirus. Microbiol Spectr. 2016;4(4). 
39. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al. Estimation of 
the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. 
Rev Med Virol. 2019;29(3):e2034. 
 
 55 
40. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 
2015;235(2):288-97. 
41. Stowell JD, Forlin-Passoni D, Din E, Radford K, Brown D, White A, et al. Cytomegalovirus 
survival on common environmental surfaces: opportunities for viral transmission. J Infect Dis. 
2012;205(2):211-4. 
42. Levy JA, Ferro F, Greenspan D, Lennette ET. Frequent isolation of HHV-6 from saliva and 
high seroprevalence of the virus in the population. Lancet. 1990;335(8697):1047-50. 
43. Daibata M, Taguchi T, Nemoto Y, Taguchi H, Miyoshi I. Inheritance of chromosomally 
integrated human herpesvirus 6 DNA. Blood. 1999;94(5):1545-9. 
44. Pellett PE, Ablashi DV, Ambros PF, Agut H, Caserta MT, Descamps V, et al. 
Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol. 
2012;22(3):144-55. 
45. Frappier L. EBNA1 and host factors in Epstein-Barr virus latent DNA replication. Curr Opin 
Virol. 2012;2(6):733-9. 
46. Reddehase MJ, Simon CO, Seckert CK, Lemmermann N, Grzimek NK. Murine model of 
cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol. 2008;325:315-31. 
47. Elder E, Sinclair J. HCMV latency: what regulates the regulators? Med Microbiol Immunol. 
2019;208(3-4):431-8. 
48. Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med. 
2007;120(10):911 e1-8. 
49. Dunn HS, Haney DJ, Ghanekar SA, Stepick-Biek P, Lewis DB, Maecker HT. Dynamics of 
CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis. 
2002;186(1):15-22. 
50. Reeves M, Sinclair J. Aspects of human cytomegalovirus latency and reactivation. Curr Top 
Microbiol Immunol. 2008;325:297-313. 
51. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, et al. Identification of 
human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988;1(8594):1065-7. 
52. Stone RC, Micali GA, Schwartz RA. Roseola infantum and its causal human herpesviruses. 
Int J Dermatol. 2014;53(4):397-403. 
53. Kondo K, Yamanishi K. Chapter 47: HHV-6A, 6B, and 7: molecular basis of latency and 
reactivation.  Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis: Cambridge 
University Press 2007; 2007. 
54. Pantry SN, Medveczky PG. Latency, Integration, and Reactivation of Human Herpesvirus-6. 
Viruses. 2017;9(7). 
55. Qiu J, Söderlund-Venermo M, Young NS. Human Parvoviruses. Clin Microbiol Rev. 
2017;30(1):43-113. 
56. Tewary SK, Zhao H, Deng X, Qiu J, Tang L. The human parvovirus B19 non-structural 
protein 1 N-terminal domain specifically binds to the origin of replication in the viral DNA. 
Virology. 2014;449:297-303. 
57. Bönsch C, Zuercher C, Lieby P, Kempf C, Ros C. The globoside receptor triggers structural 
changes in the B19 virus capsid that facilitate virus internalization. J Virol. 
2010;84(22):11737-46. 
58. Young N, Harrison M, Moore J, Mortimer P, Humphries RK. Direct demonstration of the 




59. Yaegashi N, Shiraishi H, Takeshita T, Nakamura M, Yajima A, Sugamura K. Propagation of 
human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J 
Virol. 1989;63(6):2422-6. 
60. Söderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K. Persistence of 
human parvovirus B19 in human tissues. Pathol Biol (Paris). 2002;50(5):307-16. 
61. Norja P, Hokynar K, Aaltonen LM, Chen R, Ranki A, Partio EK, et al. Bioportfolio: lifelong 
persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl 
Acad Sci U S A. 2006;103(19):7450-3. 
62. Toppinen M, Perdomo MF, Palo JU, Simmonds P, Lycett SJ, Söderlund-Venermo M, et al. 
Bones hold the key to DNA virus history and epidemiology. Sci Rep. 2015;5:17226. 
63. Ahsan N, Ed. Polyomaviruses and Human Diseases, Advances in Experimental, Medicine 
and Biology. New York, U.S.A.: Springer Science+Business Media; 2006. 
64. Pastrana DV, Ray U, Magaldi TG, Schowalter RM, Çuburu N, Buck CB. BK polyomavirus 
genotypes represent distinct serotypes with distinct entry tropism. J Virol. 
2013;87(18):10105-13. 
65. Dörries K, Vogel E, Günther S, Czub S. Infection of human polyomaviruses JC and BK in 
peripheral blood leukocytes from immunocompetent individuals. Virology. 1994;198(1):59-
70. 
66. Goudsmit J, Wertheim-van Dillen P, van Strien A, van der Noordaa J. The role of BK virus in 
acute respiratory tract disease and the presence of BKV DNA in tonsils. J Med Virol. 
1982;10(2):91-9. 
67. Sundsfjord A, Spein AR, Lucht E, Flaegstad T, Seternes OM, Traavik T. Detection of BK 
virus DNA in nasopharyngeal aspirates from children with respiratory infections but not in 
saliva from immunodeficient and immunocompetent adult patients. J Clin Microbiol. 
1994;32(5):1390-4. 
68. Pena GPA, Mendes GS, Dias HG, Gavazzoni LS, Amorim AR, Santos N. Human 
polyomavirus KI, WU, BK, and JC in healthy volunteers. Eur J Clin Microbiol Infect Dis. 
2019;38(1):135-9. 
69. Zhong S, Zheng HY, Suzuki M, Chen Q, Ikegaya H, Aoki N, et al. Age-related urinary 
excretion of BK polyomavirus by nonimmunocompromised individuals. J Clin Microbiol. 
2007;45(1):193-8. 
70. Husseiny MI, Anastasi B, Singer J, Lacey SF. A comparative study of Merkel cell, BK and JC 
polyomavirus infections in renal transplant recipients and healthy subjects. J Clin Virol. 
2010;49(2):137-40. 
71. Harvey A, Champe P, Editors. Immunology Lippincott´s Illustrated Reviews. Baltimore, 
Philadelphia: Wolters Kluwer, Lippincott Williams & Wilkins; 2008. 
72. Lester SN, Li K. Toll-like receptors in antiviral innate immunity. J Mol Biol. 
2014;426(6):1246-64. 
73. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat 
Immunol. 2015;16(4):343-53. 
74. Mahla RS, Reddy MC, Prasad DV, Kumar H. Sweeten PAMPs: Role of Sugar Complexed 
PAMPs in Innate Immunity and Vaccine Biology. Front Immunol. 2013;4:248. 
75. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate 
immunity.  Nat Rev Immunol. England2013. p. 453-60. 




77. Bermejo-Jambrina M, Eder J, Helgers LC, Hertoghs N, Nijmeijer BM, Stunnenberg M, et al. 
C-Type Lectin Receptors in Antiviral Immunity and Viral Escape. Front Immunol. 
2018;9:590. 
78. Mercer J, Greber UF. Virus interactions with endocytic pathways in macrophages and 
dendritic cells. Trends Microbiol. 2013;21(8):380-8. 
79. Loo YM, Gale M, Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680-
92. 
80. Kapoor A, Forman M, Arav-Boger R. Activation of nucleotide oligomerization domain 2 
(NOD2) by human cytomegalovirus initiates innate immune responses and restricts virus 
replication. PLoS One. 2014;9(3):e92704. 
81. Chen N, Xia P, Li S, Zhang T, Wang TT, Zhu J. RNA sensors of the innate immune system 
and their detection of pathogens. IUBMB Life. 2017;69(5):297-304. 
82. Barber GN. Cytoplasmic DNA innate immune pathways. Immunol Rev. 2011;243(1):99-108. 
83. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the 
interferon regulatory factor family of transcription factors. Immunity. 2006;25(3):349-60. 
84. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive 
immune responses. Adv Immunol. 2007;96:41-101. 
85. Nierkens S, Tel J, Janssen E, Adema GJ. Antigen cross-presentation by dendritic cell subsets: 
one general or all sergeants? Trends Immunol. 2013;34(8):361-70. 
86. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 
2006;124(4):783-801. 
87. Sichien D, Lambrecht BN, Guilliams M, Scott CL. Development of conventional dendritic 
cells: from common bone marrow progenitors to multiple subsets in peripheral tissues. 
Mucosal Immunol. 2017;10(4):831-44. 
88. van Kooyk Y, Unger WW, Fehres CM, Kalay H, García-Vallejo JJ. Glycan-based DC-SIGN 
targeting vaccines to enhance antigen cross-presentation. Mol Immunol. 2013;55(2):143-5. 
89. Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev 
Immunol. 2015;15(8):471-85. 
90. Atri C, Guerfali FZ, Laouini D. Role of Human Macrophage Polarization in Inflammation 
during Infectious Diseases. Int J Mol Sci. 2018;19(6). 
91. Kawabe T, Matsushima M, Hashimoto N, Imaizumi K, Hasegawa Y. CD40/CD40 ligand 
interactions in immune responses and pulmonary immunity. Nagoya J Med Sci. 2011;73(3-
4):69-78. 
92. Guan J, Miah SM, Wilson ZS, Erick TK, Banh C, Brossay L. Role of type I interferon 
receptor signaling on NK cell development and functions. PLoS One. 2014;9(10):e111302. 
93. Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-
mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence 
and clinical perspectives. Ann Transl Med. 2019;7(5):105. 
94. Mah AY, Cooper MA. Metabolic Regulation of Natural Killer Cell IFN-γ Production. Crit 
Rev Immunol. 2016;36(2):131-47. 
95. Pahl JHW, Cerwenka A, Ni J. Memory-Like NK Cells: Remembering a Previous Activation 
by Cytokines and NK Cell Receptors. Front Immunol. 2018;9:2796. 
96. Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector and memory CD8 T-cell trafficking: 
parallels and distinctions. Immunotherapy. 2011;3(10):1223-33. 
 
58 
97. Sckisel GD, Bouchlaka MN, Monjazeb AM, Crittenden M, Curti BD, Wilkins DE, et al. Out-
of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity. Immunity. 
2015;43(2):240-50. 
98. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 
2011;35(2):161-8. 
99. Le Gallou S, Caron G, Delaloy C, Rossille D, Tarte K, Fest T. IL-2 requirement for human 
plasma cell generation: coupling differentiation and proliferation by enhancing MAPK-ERK 
signaling. J Immunol. 2012;189(1):161-73. 
100. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557-69. 
101. Cosmi L, Maggi L, Santarlasci V, Liotta F, Annunziato F. T helper cells plasticity in 
inflammation. Cytometry A. 2014;85(1):36-42. 
102. Wu C, Xue Y, Wang P, Lin L, Liu Q, Li N, et al. IFN-γ primes macrophage activation by 
increasing phosphatase and tensin homolog via downregulation of miR-3473b. J Immunol. 
2014;193(6):3036-44. 
103. Jameson SC, Masopust D. Understanding Subset Diversity in T Cell Memory. Immunity. 
2018;48(2):214-26. 
104. Hoffman W, Lakkis FG, Chalasani G. B Cells, Antibodies, and More. Clin J Am Soc 
Nephrol. 2016;11(1):137-54. 
105. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting 
plasma cells. Nat Rev Immunol. 2015;15(3):160-71. 
106. Schmaier A, Perruzzelli L. Hematology for the Medical Student: Lippincott Williams & 
Wilcott; 2003. 
107. Krafts K. The Complete (but not obsessive) Hematopathology Guide, e-book. Minnesota: 
www.pathologystudent.com; 2017. 
108. Provan D, Singer C, Baglin T, Lilleyman J. Provan D, Singer CRJ, Oxford handbook of 
clinical haematology second edition: Oxford University Press; 2004. 
109. Li J. Myelodysplastic syndrome hematopoietic stem cell. Int J Cancer. 2013;133(3):525-33. 
110. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, et al. 
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem 
cells. Leukemia. 2010;24(4):756-64. 
111. Svahn B-M, Ringdén O, Ljungman P, Winiarski J. Information om allogen 
stamcellstransplantation [Internet]. Stockholm: Karolinska Universitetssjukhuset Huddinge; 
2011. Available from: https://www.karolinska.se/globalassets/global/4-gamla-
kataloger/cast/patientbroschyr-om-allogen-stamcellstransplantation-2012.pdf?id=11533. 
112. Langenskiöld C. RUTIN SCT - HLA-typning och val av donator [Internet]. Göteborg: 
Sahlgrenska Universitetssjukhuset; 2019 [updated 2019-11-18]. Available from: 
https://alfresco.vgregion.se/alfresco/service/vgr/storage/node/content/19925/SCT-%20HLA-
typning%20och%20val%20av%20donator.pdf?a=false&guest=true. 
113. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: 
one size does not fit all. Blood. 2014;124(3):344-53. 
114. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. 
Leukemia. 2007;21(7):1387-94. 
115. Borel J. Immunosuppression.  Encyclopedia of Immunology (Second Edition): 
Transplantation Research, Novartis Pharma Inc; 1998. p. 1349-53. 
 
 59 
116. FASS. Lemtrada [Internet]. Stockholm: LIF Läkemedelsindustriföreningens Service AB;  
[updated 2018-02-26 ]. Available from: 
https://www.fass.se/LIF/product?userType=0&nplId=20121223000012#pharmacodynamic. 
117. Mullis KB, Erlich HA, Arnheim N, Horn GT, Saiki RK, Scharf SJ, inventors; Process for 
amplifying, detecting, and/or cloning nucleic acid sequences. USA1986. 
118. Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic amplification of 
DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol. 1986;51 Pt 
1:263-73. 
119. Chien A, Edgar DB, Trela JM. Deoxyribonucleic acid polymerase from the extreme 
thermophile Thermus aquaticus. J Bacteriol. 1976;127(3):1550-7. 
120. Kamolvarin N, Tirawatnpong T, Rattanasiwamoke R, Tirawatnpong S, Panpanich T, 
Hemachudha T. Diagnosis of rabies by polymerase chain reaction with nested primers. J 
Infect Dis. 1993;167(1):207-10. 
121. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of 
immunoglobulin G. Immunochemistry. 1971;8(9):871-4. 
122. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-
linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J 
Immunol Methods. 1983;65(1-2):109-21. 
123. Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringdén O. A comparison of 
nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. 
Transplantation. 2004;78(7):1014-20. 
124. Heim A, Ebnet C, Harste G, Pring-Akerblom P. Rapid and quantitative detection of human 
adenovirus DNA by real-time PCR. J Med Virol. 2003;70(2):228-39. 
125. Lindblom A, Isa A, Norbeck O, Wolf S, Johansson B, Broliden K, et al. Slow clearance of 
human parvovirus B19 viremia following acute infection. Clin Infect Dis. 2005;41(8):1201-3. 
126. Broliden K, Tolfvenstam T, Ohlsson S, Henter JI. Persistent B19 parvovirus infection in 
pediatric malignancies. Med Pediatr Oncol. 1998;31(2):66-72. 
127. Yip CCY, Sridhar S, Cheng AKW, Fung AMY, Cheng VCC, Chan KH, et al. Comparative 
evaluation of a laboratory developed real-time PCR assay and the RealStar(®) HHV-6 PCR 
Kit for quantitative detection of human herpesvirus 6. J Virol Methods. 2017;246:112-6. 
128. Group E. Puteaux, France. Available from: https://www.elitechgroup.com/. 
129. Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. Adenovirus infections in patients 
undergoing bone-marrow transplantation. N Engl J Med. 1985;312(9):529-33. 
130. Baldwin A, Kingman H, Darville M, Foot AB, Grier D, Cornish JM, et al. Outcome and 
clinical course of 100 patients with adenovirus infection following bone marrow 
transplantation. Bone Marrow Transplant. 2000;26(12):1333-8. 
131. Lion T, Baumgartinger R, Watzinger F, Matthes-Martin S, Suda M, Preuner S, et al. 
Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow 
transplantation permits early diagnosis of disseminated disease. Blood. 2003;102(3):1114-20. 
132. Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE, et al. 
Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome 
in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 
2002;100(5):1619-27. 
133. Matthes-Martin S, Feuchtinger T, Shaw PJ, Engelhard D, Hirsch HH, Cordonnier C, et al. 
European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem 
cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14(6):555-63. 
 
60 
134. Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS. Persistent B19 parvovirus 
infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. 
Lancet. 1988;2(8621):1159-62. 
135. Heegaard ED, Jensen L, Hornsleth A, Schmiegelow K. The role of parvovirus B19 infection 
in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1999;16(4):329-34. 
136. Fattet S, Cassinotti P, Popovic MB. Persistent human parvovirus B19 infection in children 
under maintenance chemotherapy for acute lymphocytic leukemia. J Pediatr Hematol Oncol. 
2004;26(8):497-503. 
137. El-Mahallawy HA, Mansour T, El-Din SE, Hafez M, Abd-el-Latif S. Parvovirus B19 
infection as a cause of anemia in pediatric acute lymphoblastic leukemia patients during 
maintenance chemotherapy. J Pediatr Hematol Oncol. 2004;26(7):403-6. 
138. Yoto Y, Kudoh T, Suzuki N, Matsunaga Y, Chiba S. Retrospective study on the influence of 
human parvovirus B19 infection among children with malignant diseases. Acta Haematol. 
1993;90(1):8-12. 
139. Soliman Oel S, Abd El-Aal Hegazi Hasan M, El-Ashry R, Zaghloul MH, Kora B. Parvovirus 
B19 infection in pediatric oncology patients: diagnostic value of clinical and serologic 
parameters compared with nested PCR. J Pediatr Hematol Oncol. 2009;31(3):173-6. 
140. Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A. Prevalence of parvovirus B19 and 
parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy 
individuals. J Clin Microbiol. 2002;40(3):933-6. 
141. Lundqvist A, Tolfvenstam T, Brytting M, Stolt CM, Hedman K, Broliden K. Prevalence of 
parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand J 
Infect Dis. 1999;31(2):119-22. 
142. Barncancerfonden. Behandling av Akut lymfatisk leukemi [Internet]. Stockholm: 
Barncancerfonden; 2008. Available from: 
https://www.barncancerfonden.se/contentassets/767145c295904911b291d97ff037e055/behan
dlingsprotokoll-all-2008.pdf. 
143. Heegaard ED, Schmiegelow K. Serologic study on parvovirus b19 infection in childhood 
acute lymphoblastic leukemia during chemotherapy: clinical and hematologic implications. J 
Pediatr Hematol Oncol. 2002;24(5):368-73. 
144. Söderlund M, Ruutu P, Ruutu T, Asikainen K, Franssila R, Hedman K. Primary and 
secondary infections by human parvovirus B19 following bone marrow transplantation: 
characterization by PCR and B-cell molecular immunology. Scand J Infect Dis. 
1997;29(2):129-35. 
145. Takano T, Yamada K. Quantitation of human parvovirus B19 DNA by real-time polymerase 
chain reaction. Pediatr Int. 2007;49(4):459-62. 
146. Maple PA, Hedman L, Dhanilall P, Kantola K, Nurmi V, Söderlund-Venermo M, et al. 
Identification of past and recent parvovirus B19 infection in immunocompetent individuals by 
quantitative PCR and enzyme immunoassays: a dual-laboratory study. J Clin Microbiol. 
2014;52(3):947-56. 
147. Pambrun E, Mengelle C, Fillola G, Laharrague P, Esposito L, Cardeau-Desangles I, et al. An 
Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-
Transplant Recipients. J Transplant. 2014;2014:252914. 
148. Eid AJ, Ardura MI, Practice ASTIDCo. Human parvovirus B19 in solid organ 
transplantation: Guidelines from the American society of transplantation infectious diseases 
community of practice. Clin Transplant. 2019;33(9):e13535. 
 
 61 
149. Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a 
recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis. 
2003;187(4):675-8. 
150. Bernstein DI, El Sahly HM, Keitel WA, Wolff M, Simone G, Segawa C, et al. Safety and 
immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011;29(43):7357-63. 
151. Dalianis T, Eriksson B-M, Felldin M, Friman V, Hammarin A-L, Hertherlius M, et al. 
Handläggning av BK-virus infektion - Rekommendation 2018. 2018 [2020-10-21]. Available 
from: 
https://www.sls.se/globalassets/rav/rekommendationer/bkv_rekommendation_181029.pdf. 
152. Amplyx Pharmaceuticals S-D. Amplyx doses first patient in phase 2 clinical trial of anti-BKV 
monoclonal antibody in renal transplant recipients. 2020 [2020-10-21]. Available from: 
https://amplyx.com/amplyx-doses-first-patient-in-phase-2-clinical-trial-of-anti-bkv-
monoclonal-antibody-in-renal-transplant-recipients/. 
153. Ward KN, Hill JA, Hubacek P, de la Camara R, Crocchiolo R, Einsele H, et al. Guidelines 
from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 
infection in patients with hematologic malignancies and after hematopoietic stem cell 
transplantation. Haematologica. 2019;104(11):2155-63. 
 
